

# Validity of Dried Blood Spot Testing for Sexually Transmitted and Blood-Borne Infections: A Narrative Systematic Review

François Cholette<sup>1,2,&,\*</sup>, Simone Périnet<sup>3,&</sup>, Bronwyn Neufeld<sup>1,&</sup>, Maggie Bryson<sup>4</sup>, Jennifer Macri<sup>5</sup>, Kathryn M. Sibley<sup>6,7</sup>, John Kim<sup>1</sup>, S. Michelle Driedger<sup>6</sup>, Marissa L. Becker<sup>6</sup>, Paul Sandstrom<sup>1,2</sup>, Adrienne F. A. Meyers<sup>1,2</sup>, Dana Paquette<sup>4,8</sup>

<sup>1</sup>National Sexually Transmitted and Blood Borne Infection Laboratory, National Microbiology Laboratory at the J. C. Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada

<sup>2</sup>Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada

<sup>3</sup>Sexually Transmitted and Blood Borne Infection Surveillance Division, Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Canada

<sup>4</sup>Horizontal Surveillance Operations Division, Centre for Corporate Surveillance Coordination, Public Health Agency of Canada, Ottawa, Canada

<sup>5</sup>Office of Public Health Field Services and Training, Center for Emergency Preparedness, Public Health Agency of Canada, Ottawa, Canada

<sup>6</sup>Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada

<sup>7</sup>George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, Canada

<sup>8</sup>School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada

&These authors contributed equally to this work.

\*Corresponding author: François Cholette

National Sexually Transmitted and Blood Borne Infection Laboratory

National Microbiology Laboratory at the J. C. Wilt Infectious Diseases Research Centre

Public Health Agency of Canada

745 Logan Ave., Winnipeg, Manitoba R3E 3L5

Tel: +1 (204) 789-6513

Email: [Francois.Cholette@phac-aspc.gc.ca](mailto:Francois.Cholette@phac-aspc.gc.ca)

## Declarations

**Funding:** KMS is supported by a Tier 2 Canada Research Chair in Integrated Knowledge Translation in Rehabilitation Sciences.

**Conflict of interest:** The authors declare no competing interests.

**Ethics approval:** Not applicable.

**Consent to participate:** Not applicable.

**Consent for publication:** Not applicable.

**Availability of data and material:** All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

**Code availability:** Not applicable.

**Author contributions:** FC, SP, BN, and JM performed data analysis, curated data, and wrote the initial draft. FC, MB, KMS, JK, SMD, MB, and DP conceived and designed the protocol. MB, KMS, JK, SMD, MB, PS, AM, and DP provided supervision and critical review of the initial draft.

## Word Count

Abstract: 239

Body of the text: 3400

# Abstract

**Objective:** Testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) using dried blood spot (DBS) specimens has been an integral part of bio-behavioural surveillance in Canada for almost two decades. A systematic review was conducted to assess the current evidence regarding the validity of sexually transmitted and blood-borne infection (STBBI) testing using DBS specimens.

**Methods:** A literature search was conducted using a peer-reviewed search strategy. Eligibility criteria included studies reporting use of DBS specimens for STBBI testing in populations 15 years of age or older. The intervention of interest was either commercially available or “in-house” tests used to detect STBBI from DBS specimens. Studies that reported a measure of validity such as sensitivity, specificity, positive and negative predictive values were eligible for inclusion. Quality of studies and risk of bias were assessed using the QUADAS-2 tool.

**Results:** A total of 6,706 records were identified. Of these records, 169 full-text articles met the criteria for inclusion. The STBBI with the most articles reporting a measure of validity for testing on DBS was HIV ( $n=73$ ), followed by HCV ( $n=63$ ), HBV ( $n=33$ ), syphilis ( $n=7$ ), HAV ( $n=5$ ), HSV ( $n=5$ ), HTLV ( $n=3$ ), and HPV ( $n=1$ ). The majority of studies reported high sensitivity ( $\geq 90\%$ ) and specificity ( $\geq 90\%$ ). However, the quality of the studies varied greatly. No evidence was found on the validity of chlamydia and gonorrhoea testing using DBS specimens.

**Conclusion:** Our findings support the validity of DBS testing for STBBI surveillance where sufficient evidence was available, but validity is highly dependent on thorough method development and validation.

**Keywords:** dried blood spot testing, sexually transmitted diseases, blood-borne infections, biosurveillance

## Introduction

Dried blood spot (DBS) specimens consist of blood spotted and dried on filter paper. They have been used for biological sampling in clinical and research settings for nearly a century (Gruner, Stambouli, & Ross, 2015; Malsagova et al., 2020). Compared to conventional biological specimens like plasma or serum, DBS offers several advantages, including high acceptability among research participants (Landy et al., 2022) and compatibility with self-collection (Takano et al., 2018). DBS specimens are also stable at room temperature and do not require refrigeration during transportation, providing opportunities for biological sampling in remote and isolated communities (Lim, 2018). DBS sampling is typically deployed in resource-constrained settings for infectious disease diagnostics (Sherman, Stevens, Jones, Horsfield, & Stevens, 2005), surveillance (Buckton, 2008), and patient monitoring (Chevaliez & Pawlotsky, 2018), but it also has the potential to be an effective tool for infectious disease surveillance in high resource settings like Canada given the country's numerous northern, remote, and isolated communities scattered across challenging geography. DBS sampling has also been shown to have a high acceptability as an approach of screening for sexually transmitted and blood-borne infections (STBBIs) in communities across Canada (Landy et al., 2022; Young et al., 2022).

DBS sampling was thrust into the spotlight during the COVID-19 pandemic, as it became routine for surveillance and epidemiological studies while limiting face-to-face interactions and overcoming healthcare staff shortages by allowing individuals to reliably collect their samples at home (Miesse, Collier, & Grant, 2022). For example, Statistics Canada's Canadian COVID-19 Antibody and Health Survey (CCAHS) relied on DBS self-collection to assess COVID-19 seroprevalence nationally ([www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5339](http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5339)). As a result, lessons learned from implementing large-scale DBS sampling for SARS-CoV-2 surveillance could inform STBBI surveillance moving forward.

Diagnostic assays have shown excellent clinical performance on DBS specimens. Most validation studies have been performed for HIV screening, but more recent studies have demonstrated the feasibility of using DBS specimens for the diagnosis of viral hepatitis (Tuaille et al., 2010). However, it is difficult to ascertain if DBS are a suitable specimen for STBBI surveillance considering the many experimental conditions (i.e. DBS punching and

elution protocols), combinations of reference and index tests, and study populations. Special consideration is also needed for key populations where dual-infections are more prevalent, including HCV/HIV co-infection among people who inject drugs and HIV/syphilis co-infection in men who have sex with men (Gobran, Ancuta, & Shoukry, 2021; Roberts & Klausner, 2016). The presence of dual-infections is important to consider as it may have the potential to impact assay performance (McArdle, Turkova, & Cunningham, 2018). However, most validation studies focus on a single STBBI and therefore performance metrics are presented for a single index test, pathogen, and population, making it difficult to draw broader conclusions on the validity of using DBS specimens for STBBI surveillance.

The objective of this systematic review is to compile data on measures of validity to ascertain if the current literature supports the use of DBS, in the context of surveillance, for the detection of the following STBBI: HIV-1, HIV-2, hepatitis viruses (A, B, and C), herpes simplex virus (type 1 and 2), human T-cell lymphotropic virus (type 1 and 2), human papilloma virus, chlamydia (*Chlamydia trachomatis*), gonorrhoea (*Neisseria gonorrhoeae*), and syphilis (*Treponema pallidum*). Measures of validity include sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), limit of quantification (LOQ), and/or limit of detection (LOD). Additionally, we aim to identify factors which may influence test performance.

## Methods

### Information Sources

Peer-reviewed original research was identified by searching Excerpta Medica dataBASE (EMBASE), Medical Literature Analysis and Retrieval System Online (Ovid MEDLINE) and Elsevier Scopus. Grey literature was identified by searching key websites including Public Health Ontario, BC Centre for Excellence in HIV/AIDS, Canadian AIDS Treatment Information Exchange (CATIE), Institut national d'excellence en santé et services sociaux, Open Grey, Public Health Agency of Canada, American Society of Microbiology, Infectious Disease Society of America, American Society of Virology, International AIDS Society, International Society for Sexually Transmitted Diseases Research, Conference on Retroviruses and Opportunistic Infections (CROI), International AIDS Conference, Centre for Disease Control (CDC), Public Health England, European Centre for Disease Prevention and Control, World Health Organization (WHO) and the French National Agency for AIDS Research (ANRS).

### Search Strategy

Literature searching was conducted under the guidance of a librarian (Janice Linton, University of Manitoba) using a peer-reviewed search strategy (McGowan et al., 2016). The search strategy consisted of both controlled vocabulary such as the National Library of Medicine’s MeSH (medical subject heading) and keywords (Supplementary File 1). Retrieval was limited to human populations, English and French language documents, and results were not limited by publication date up to May 2022.

### Eligibility Criteria

Populations were eligible if they provided DBS specimens tested for the following STBBIs: human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2), hepatitis virus A, B, and C (HAV, HBV, and HCV), human T-cell lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2), human papilloma virus (HPV), *Chlamydia trachomatis* (chlamydia), *Neisseria gonorrhea* (gonorrhoeae) and *Treponema pallidum* (syphilis). Studies were eligible if they were conducted on populations 15 years of age or older, regardless of socio-demographic characteristics and setting.

The intervention of interest was either commercially available or in-house tests used to detect STBBIs from DBS specimens. Inclusion criteria for commercial tests were limited to 3<sup>rd</sup> generation or greater enzyme immunoassays (EIAs) and nucleic acid tests, since older HIV testing methodologies (i.e., 1<sup>st</sup> and 2<sup>nd</sup> generation EIAs) are likely no longer manufactured (Alexander, 2016), and therefore are irrelevant.

The intervention was compared to either commercially available or in-house tests used to detect STBBIs from “gold-standard” biological specimens (ex: whole blood, plasma and serum) used for routine STBBI testing. Commercial tests were limited to 3<sup>rd</sup> generation or greater EIAs and nucleic acid tests.

Included studies had to report measures of the intervention’s validity such as sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), limit of quantification (LOQ) and/or limit of detection (LOD).

### Exclusion Criteria

Peer-reviewed or grey literature were excluded if (1) the pathogen of interest was not included in the list of STBBIs mentioned above, (2) measures of the testing methodology’s validity were not reported, (3) biological specimens other than blood were collected on filter paper, (4) DBS were used to measure adherence to pre-exposure prophylaxis and/or anti-retroviral medication, (5) DBS were analyzed for the purpose of investigation of drug resistance or genotyping, (6) participants were under 15 years of age, (7) the intervention was out of scope (i.e., blood

dried on matrix other than filter paper), (8) the work was not original research, or (9) the reports were in a language other than English or French.

## **Document Screening**

Titles and abstracts were initially screened by one reviewer (FC or BN) with 10% peer-reviewed by a second reviewer (SP or FC). A full-text review was then conducted of potential articles for inclusion by one reviewer (FC or BN) with 10% being peer-reviewed by a second reviewer (SP or FC). Disagreements were resolved by a third reviewer (MB).

## **Data Extraction**

Data was collected from each document on the inclusion list (e.g., study population, sampling method, sample size, index test, reference test, STBBI, DBS preparation method, sensitivity, specificity, accuracy, PPV, NPV, LOQ and/or LOD) and entered into a standardized table. For each document, descriptive data were also extracted, including information on the authors, year of publication, country, setting, participant characteristics, description of the intervention, description of the comparators, and other key findings related to the research question. One reviewer (FC or BN) extracted descriptive and outcome data, while a second reviewer (SP or FC) was responsible for verifying the data extraction for accuracy.

## **Quality Assessment**

The QUADAS-2 tool was used to assess the quality and risk of bias of each document retained for data extraction to critically appraise the validity of DBS testing (Whiting et al., 2006). One reviewer (FC or BN) assessed the quality of each document using the QUADAS-2 tool available from the QUADAS website ([www.quadas.org](http://www.quadas.org)), and a second reviewer (SP or FC) verified the assessment. A third reviewer, MB, resolved disagreements.

## **Data Analysis**

Data extracted from selected documents were synthesized through a narrative synthesis approach (Mays, Pope, & Popay, 2005). A narrative approach to synthesis was chosen because we had anticipated significant heterogeneity among documents in terms of context, patient populations, and index tests. Synthesized findings were compiled in tabulated form organized by STBBI, population, sample size, index test, and collection method. In addition, inductive thematic analysis was conducted in order to identify key themes and relationships in included studies.

## Results

We identified 7,631 abstracts in database searches. After 925 duplicates were removed, 6,706 titles and abstracts were screened, and 6,139 excluded. 567 reports were assessed for eligibility, with 397 further excluded. Of these, 230 were excluded due to no available data on measures of validity, 52 were excluded based on the study intervention, and 31 did not have full-text reports available. A further 23 studies were excluded for utilizing specimens other than blood, while 22 reports involved ineligible populations, and 15 were conducted for the purposes of genotyping or drug resistance studies designating them ineligible for inclusion. 16 studies were deemed ineligible on the basis of being unoriginal research. Eight reports were excluded as they were written in languages other than English or French. A total of 168 studies met the inclusion criteria and were included in the review. A PRISMA flow diagram (Page et al., 2021) representing the study selection is shown in Figure 1.

## Study Characteristics

Characteristics of included studies are summarized in Supplementary File 2. A large proportion of included studies reported on the use of DBS for HIV testing ( $n=73$ ; 43.5%). The remaining studies ( $n=115$ ) reported on HCV ( $n=62$ ; 36.9%), HBV ( $n=33$ ; 19.6%), syphilis ( $n=7$ ; 4.2%), HAV ( $n=5$ ; 3.0%), HSV ( $n=4$ ; 2.4%), HTLV ( $n=3$ ; 1.8%), and HPV ( $n=1$ ; 0.6%). No studies reported on chlamydia or gonorrhea. Several studies reported on more than one STBBI (e.g., (Villar et al., 2011)), leading to a total of outcomes above the total number of studies included in this systematic review.

## STBBI Test Performance with DBS Specimens

Overall, included studies demonstrated high sensitivity and specificity for STBBI testing with DBS specimens (Fig. 2). HIV studies reported a wide range of values for sensitivity (9.0 to 100%) and specificity (4.0 to 100%). The majority of sensitivity measurements ( $n=137$ ; 55.0%) were equal to or above 90.0%. Specificity measurements were also high, with most observations ( $n=172$ ; 79.3%) above 90.0%. HCV studies reported sensitivity and specificity ranging from 36.0% to 100% and 85.7% to 100%, respectively. Most sensitivity ( $n=130$ ; 77.4%) and specificity ( $n=116$ ; 98.3%) measurements concerning HCV were equal to or above 90.0%. HBV studies reported sensitivity and specificity ranging from 40.0% to 100% and 2.5% to 100%, respectively. Approximately half of sensitivity measurements ( $n=34$ ; 47.2%) and most specificity ( $n=60$ ; 83.3%) measurements concerning HBV were equal



to or above 90.0%. Studies involving syphilis reported high sensitivity and specificity, with ranges of 90.0% to 100% and 99.0% to 100%, respectively. HAV studies reported sensitivity and specificity ranging from 31.0% to 100% and 75.0% to 100%, respectively. Most sensitivity ( $n=4$ ; 66.7%) and specificity ( $n=5$ ; 83.3%) measurements concerning HAV were equal to or above 90.0%. HSV studies reported sensitivity and specificity ranging from 9.0% to 100% and 4.5% to 100%, respectively. Most sensitivity measurements ( $n=5$ ; 55.6%) and almost half of specificity measurements ( $n=4$ ; 44.4%) concerning HSV were equal to or above 90.0%. HTLV studies reported a range in sensitivity of 81.0% to 100%, while all included studies reported 100% specificity. The single HPV study reported an overall sensitivity and specificity of 98.0% and 92.0%, respectively. Approximately one-quarter of studies ( $n=47$ ; 27.8%) reported LOD and/or LOQ values (Table 1). A meta-analysis was not undertaken due to the significant methodological heterogeneity among the included studies. This led us to identify several parameters that could influence index test performance.

# **Test Cut-Offs**

Studies generally reported improved test performance by adjusting cut-off values – typically optimized for serum/plasma by manufacturers – for DBS specimens (Table 2). For example, García-Cisneros et al. (García-Cisneros et al., 2019) found that the IgG-G2 Human ELISA test (Human Diagnostics, Germany; HSV-2) performed better on DBS (specificity of 4.5% [95% CI=3%, 6.5%] versus 87.1% [95% CI=81.2%, 91.4%]) when using a cut-off value based on a receiver operating characteristic (ROC) curve. Villar et al. (Villar et al., 2011) also observed lower sensitivity (95.5% [95% CI=84.5%, 99.4%] versus 97.6% [95% CI=87.4%, 99.9%]; ETI-MAK-4 test, DiaSorin) and specificity (81.3% [95% CI=70.7%, 89.4%] versus 97.3% [95% CI=90.7%, 99.7%]; ETI-AB-AUK-3 test, DiaSorin) values when relying on manufacturer recommended cut-offs compared to cut-off values based on ROC curve analysis for the detection of HBV in DBS specimens. Ultimately, we observed that the choice of cut-off value (manufacturer recommended versus established in-house) influenced test performance when analyzing DBS specimens.

# **DBS Specimen Preparation**

DBS specimens prepared from venous blood instead of capillary blood (i.e., finger pokes) appear to produce higher sensitivity and specificity values (Table 3). This was particularly evident with regards to HIV. Multiple studies reported better HIV serological and nucleic acid test performance when analyzing DBS specimens prepared from venous blood (Fajardo et al., 2014; Mwau et al., 2021; Rutstein et al., 2014). A few papers examined test performance

between DBS specimens prepared from venous and capillary blood for HCV testing, with the majority of those finding similar or greater sensitivity when using DBS specimens prepared with venous blood. Prinsenberget al. (Prinsenberget al., 2020) reported a small advantage in sensitivity (96.4% [95% CI=81.7%, 99.9%] versus 95.7% [78.1%, 99.9%]) when using venous blood to prepare DBS specimens, while Tran et al. (Tran et al., 2020) and Vetter et al. (Vetter et al., 2021) both reported nearly identical test performance with DBS prepared from venous and capillary blood (Table 3). In general, how DBS are prepared (venous versus capillary blood) could influence test performance, with DBS prepared from venous blood contributing to better test performance.

## Dual Infections

The presence of dual infections may influence test performance depending on the STBBI of interest (Table 4). This was particularly evident when testing for HBV and HCV on DBS collected from individuals living with HIV. Flores et al. (Flores, Cruz, Potsch, et al., 2017) reported lower sensitivity and specificity in persons living with HIV compared to those without HIV for the detection of both HBV surface antigens (HBsAg) and anti-hepatitis B core total antibodies (Anti-HBc) on the Elecsys platform (Roche; Table 4). Similar findings have also been observed in HCV testing. De Crignis et al. (De Crignis, Re, Cimatti, Zecchi, & Gibellini, 2010), Saludes et al. (Saludes et al., 2018), and Flores et al. (Flores et al., 2018) all reported reduced HCV test sensitivity in people living with HIV (Table 3). In contrast, Flores et al. (Flores et al., 2021) reported increased HCV test performance in people living with HIV compared to those who were not, but chronic kidney disease among study participants may have confounded these findings. Nonetheless, the presence of potential co-infections should be taken into consideration when validating a test for use with DBS specimens.

## Antiretroviral Therapy

In studies which included people living with HIV, assay performance was typically assessed in patients undergoing antiretroviral therapy (ART) in comparison to ART-naïve patients to detect treatment failure (Table 5). Balinda et al. (Balinda et al., 2016) reported differences in the performance of an in-house HIV RT-qPCR assay in participants living with HIV who were undergoing ART compared to those who were ART-naïve (79.4% sensitivity, 54.5% specificity), with the highest performance observed in patients who had undergone ART for longer periods (12 – 36 months; 88.9% sensitivity, 98.1% specificity). Similarly, Taeib et al. (Taeib et al., 2018) reported greater specificity in patients on ART for ≥6 months compared to those on ART for <6 months but, found no difference in sensitivity.

## Quality Assessment

All 168 included studies were assessed for quality using the QUADAS-2 tool (Fig. 3). The overall quality of studies was low, with high scores in risk of bias and applicability. Risk of bias was found to be high across most domains, with 117 studies (69.6%) rated as having high risk of bias in patient selection, 85 (50.6%) as high risk of bias for the index test, and 134 (79.8%) as high risk of bias for the reference standard. In addition, a small number ( $n=12$ ; 7.1%) of studies were rated as high risk of bias related to flow and timing. Similarly, a significant proportion of studies were rated as high concern regarding the applicability of the study to the research question. The proportion of studies rated as high concern regarding the applicability of population, index test, and reference standard was found to be 23.2%, 47.6%, and 47.6%, respectively.

## Discussion

This review describes the validity of using DBS specimens for STBBI testing. DBS specimens showed high sensitivity compared to the reference standard of plasma or serum in the included studies encompassing a wide range of experimental conditions, demonstrating a promising opportunity for the adoption of DBS specimens in STBBI testing globally. The high sensitivity and specificity observed across studies provide evidence for the suitability of DBS for the surveillance of STBBIs, including those not routinely detected in DBS specimens, such as HAV, HTLV and syphilis.

DBS specimens offer a promising alternative to plasma and serum samples for STBBI testing, though assay performance depends on several factors. We identified multiple factors which could influence test performance with DBS specimens. Adjustment of test cut-off values for DBS specimens improved overall performance (García-Cisneros et al., 2019), making it imperative for individual laboratories (or manufacturers) to validate specific cut-off values for use with DBS specimens. The presence of dual infections within a population also influenced assay performance (Flores, Cruz, Potsch, et al., 2017), resulting in decreased sensitivity, especially for HBV and HCV testing in participants living with HIV. This finding is relevant for future test development and validation for future surveillance in key populations where dual infections may be more prevalent and in geographies which experience overlapping STBBI burdens (Shayan, Nazari, & Kiwanuka, 2021). Approaches to DBS preparation (venous versus capillary blood) also affected test performance (Prinsenberget al., 2020). Although DBS prepared from venous blood

appears to offer better test performance (especially for HIV nucleic acid testing), DBS prepared from capillary blood still offer excellent test performance and reflects more closely “real-world” DBS collection, especially considering self-collection. Enhanced reporting of DBS validation studies could lead to further improvements in the performance of DBS testing using capillary blood. Finally, test performance may fluctuate depending on the duration of ART among people living with HIV. Our review supports the validity of using DBS specimens for detecting certain STBBIs. DBS specimens perform well particularly well in HIV and HCV testing, though no conclusions can be made for chlamydia or gonorrhoea surveillance as no studies investigated DBS testing with either pathogen. However, test performance relies on several experimental conditions, and standardized approaches to reporting DBS experiments should be adopted moving forward to ensure internal and external test validity.

Due to considerable heterogeneity observed across studies, we could not conduct a meta-analysis. General poor reporting of experimental conditions also created challenges in directly comparing studies – this was also reflected in our quality assessment using the QUADAS-2 tool. There is currently no consensus on how DBS studies should be reported. We propose that new standardized guidelines for reporting DBS experiments should be developed and implemented similarly to the MIQE guidelines for quantitative real-time PCR experiments (Bustin et al., 2009) or the STARD checklist (Bossuyt et al., 2015). Reporting guidelines should include the minimum information required to evaluate DBS studies, including information on DBS preparation (venous or capillary blood), drying and storage conditions, type of filter paper used, and DBS elution protocols (for example volume, type of buffer, and agitation conditions). This would allow for a more direct comparison of studies and assist in conducting robust meta-analyses to further investigate the validity of DBS specimens for STBBI testing. Though we did not record storage temperature and humidity in this review, these factors have been examined by (Amini et al., 2021) in a systematic review on on reliability of antibody measurement in DBS specimens. Though their objective differs from our review and includes fewer papers (n=40), the similar observations of heterogeneity in experimental conditions and reporting further our observation that it is necessary to record a large number of influential variables to allow for standardized assessment of studies.

While treatment failure was not explicitly part of our objective, it is an important component of surveillance. More specifically, it can provide insights into the cascade of care and progress toward HIV and HCV elimination targets (Dore & Bajis, 2021; UNAIDS, 2014). Viral load testing alone is not sufficient for the purposes of

surveillance as persons undergoing treatment may present undetectable viral loads, and therefore must be used in combination with serological assays to establish disease status. We decided to include studies investigating viral load with DBS specimens as viral load data still provide valuable insight into the cascade of care or other metrics towards elimination. It should be noted that the LOD for most HIV tests included in this review was determined to be approximately 800 copies/mL. The WHO defines virological suppression as <1,000 copies/mL, which should be reliably detected by most assays in this review (Patricia Alvarez et al., 2015; Erba et al., 2015). This finding is in agreement with a recent systematic review conducted by Vojnov et al. (2022) which concluded DBS specimens are suitable for HIV viral load testing at the treatment failure threshold of 1,000 copies/mL (Vojnov et al., 2022)[X]. Although we consider DBS specimens suitable for certain STBBI surveillance, careful attention should be paid to the LOD of each assay under consideration and consider definitions of treatment failure for the STBBI of interest.

Limitations of this review include the unavailability of any studies on DBS testing for chlamydia and gonorrhoea. We limited our biological specimen of interest to blood, and therefore did not include any papers on dried urine spots for chlamydia or gonorrhoea detection. Additionally, we were unable to conduct a meta-analysis as a result of the large amount of heterogeneity between studies. Finally, we did not examine acceptability of DBS testing among participants versus traditional methods, as this is beyond the scope of this review and warrants its own investigation.

## Conclusion

Over the course of the COVID-19 pandemic, the use of DBS specimens increased in popularity as many studies adopted them for serological studies (Cholette et al., 2022; Madhi et al., 2022; Miesse et al., 2022; Wong et al., 2022). We anticipate that this increase in DBS usage will carry forward and result in a greater number of studies using DBS specimens for STBBI testing. This review highlights the validity of DBS sampling for use in STBBI testing and identifies several key factors which influence assay performance. The use of DBS sampling presents a promising opportunity for use in STBBI surveillance in remote and isolated communities in Canada. In addition, it can benefit STBBI screening in other resource constrained settings.

## Acknowledgments

We thank Janice Linton (Indigenous Health Librarian & Liaison Librarian for Community Health Sciences at University of Manitoba, Winnipeg, Canada) for generously giving her time and assistance with the initial literature search.

## References

- Alexander, T. S. (2016). Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. *Clinical and Vaccine Immunology*, 23(4), 249-253. doi:10.1128/CVI.00053-16
- Alvarez, P., Martin, L., Prieto, L., Obiang, J., Vargas, A., Avedillo, P., . . . Holguin, A. (2015). HIV-1 Variability and Viral Load Technique Could Lead to False Positive HIV-1 Detection and to Erroneous Viral Quantification in Infected Specimens. *Journal of Infection*, 71, 368-376. doi:10.1016/j.jinf.2015.05.011
- Amini, F., Auma, E., Hsia, Y., Bilton, S., Hall, T., Ramkhelawon, L., . . . Le Doare, K. (2021). Reliability of Dried Blood Spot (DBS) Cards in Antibody Measurement: A Systematic Review. *PLoS ONE*, 16(3), e0248218. doi:10.1371/journal.pone.0248218
- Balinda, S. N., Ondo, P., Obuku, E. A., Kliphuis, A., Egau, I., Bronze, M., . . . consortium, A.-A. (2016). Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda. *PLoS ONE*, 11(1), e0145110. doi:10.1371/journal.pone.0145110
- Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., . . . Group, S. (2015). STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. *BMJ*, 351, h5527. doi:10.1136/bmj.h5527
- Buckton, A. J. (2008). New Methods for the Surveillance of HIV Drug Resistance in the Resource Poor World. *Current Opinion in Infectious Diseases*, 21(6), 653-658. doi:10.1097/QCO.0b013e3283186d1a
- Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., . . . Wittwer, C. T. (2009). The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. *Clinical Chemistry*, 55(4), 611-622. doi:10.1373/clinchem.2008.112797
- Chevaliez, S., & Pawlotsky, J. M. (2018). New Virological Tools for Screening, Diagnosis and Monitoring of Hepatitis B and C in Resource-Limited Settings. *Journal of Hepatology*, 69(4), 916-926. doi:10.1016/j.jhep.2018.05.017

- 315 Cholette, F., Fabia, R., Harris, A., Ellis, H., Cachero, K., Schroeder, L., . . . Kim, J. (2022). Comparative Performance  
316 Data for Multiplex SARS-CoV-2 Serological Assays from a Large Panel of Dried Blood Spot Specimens.  
317 *Heliyon*, 8(9), e10270. doi:10.1016/j.heliyon.2022.e10270
- 318 De Crignis, E., Re, M. C., Cimatti, L., Zecchi, L., & Gibellini, D. (2010). HIV-1 and HCV Detection in Dried Blood  
319 Spots by SYBR Green Multiplex Real-Time RT-PCR. *Journal of Virological Methods*, 165(1), 51-56.  
320 doi:10.1016/j.jviromet.2009.12.017
- 321 Dore, G. J., & Bajis, S. (2021). Hepatitis C Virus Elimination: Laying the Foundation for Achieving 2030 Targets.  
322 *Nature Reviews Gastroenterology & Hepatology*, 18(2), 91-92. doi:10.1038/s41575-020-00392-3
- 323 Erba, F., Brambilla, D., Ceffa, S., Ciccacci, F., Luhanga, R., Sidumo, Z., . . . Giuliano, M. (2015). Measurement of Viral  
324 Load by the Automated Abbott Real-Time HIV-1 Assay Using Dried Blood Spots Collected and Processed in  
325 Malawi and Mozambique. *South African Medical Journal*, 105(12), 1036-1038.  
326 doi:10.7196/SAMJ.2015.v105i12.9673
- 327 Fajardo, E., Metcalf, C. A., Chaillet, P., Aleixo, L., Pannus, P., Panunzi, I., . . . Mwenda, R. (2014). Prospective  
328 Evaluation of Diagnostic Accuracy of Dried Blood Spots from Finger Prick Samples for Determination of  
329 HIV-1 Load with the NucliSENS Easy-Q HIV-1 Version 2.0 Assay in Malawi. *Journal of Clinical Microbiology*,  
330 52(5), 1343-1351. doi:10.1128/jcm.03519-13
- 331 Flores, G. L., Barbosa, J. R., Cruz, H. M., Miguel, J. C., Potsch, D. V., Pilotto, J. H., . . . Villar, L. M. (2021). Dried Blood  
332 Spot Sampling as an Alternative for the Improvement of Hepatitis B and C Diagnosis in Key Populations.  
333 *World Journal of Hepatology*, 13(4), 504-514. doi:10.4254/wjh.v13.i4.504
- 334 Flores, G. L., Cruz, H. M., Miguel, J. C., Potsch, D. V., Pilotto, J. H., Lewis-Ximenez, L. L., . . . Villar, L. M. (2018).  
335 Assessing Hepatitis B Immunity Using Dried Blood Spot Samples from HIV+ Individuals. *Journal of Medical*  
336 *Virology*, 90(12), 1863-1867. doi:10.1002/jmv.25275
- 337 Flores, G. L., Cruz, H. M., Potsch, D. V., May, S. B., Brandao-Mello, C. E., Pires, M. M. A., . . . Villar, L. M. (2017).  
338 Evaluation of HBsAg and Anti-HBc Assays in Saliva and Dried Blood Spot Samples According HIV Status.  
339 *Journal of Virological Methods*, 247, 32-37. doi:10.1016/j.jviromet.2017.05.004
- 340 García-Cisneros, S., Sanchez-Aleman, M. A., Conde-Glez, C. J., Lara-Zaragoza, S. J., Herrera-Ortiz, A., Plett-Torres, T.,  
341 & Olamendi-Portugal, M. (2019). Performance of ELISA and Western Blot to Detect Antibodies Against

HSV-2 Using Dried Blood Spots. *Journal of Infection and Public Health*, 12(2), 224-228.  
doi:10.1016/j.jiph.2018.10.007

Gobran, S. T., Ancuta, P., & Shoukry, N. H. (2021). A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. *Frontiers in Immunology*, 12, 726419. doi:10.3389/fimmu.2021.726419

Gruner, N., Stambouli, O., & Ross, R. S. (2015). Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques. *Journal of Visualized Experiments*, 97, e52619. doi:10.3791/52619

Landy, R., Atkinson, D., Ogilvie, K., St Denys, R., Lund, C., Worthington, C., . . . team, S. (2022). Assessing the Acceptability of Dried Blood Spot Testing for HIV and STBBI Among Metis People in a Community Driven Pilot Project in Alberta, Canada. *BMC Health Services Research*, 22(1), 1496. doi:10.1186/s12913-022-08763-z

Lim, M. D. (2018). Dried Blood Spots for Global Health Diagnostics and Surveillance: Opportunities and Challenges. *American Journal of Tropical Medicine and Hygiene*, 99(2), 256-265. doi:10.4269/ajtmh.17-0889

Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., . . . Mutevedzi, P. C. (2022). Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. *New England Journal of Medicine*, 386(14), 1314-1326. doi:10.1056/NEJMoa2119658

Malsagova, K., Kopylov, A., Stepanov, A., Butkova, T., Izotov, A., & Kaysheva, A. (2020). Dried Blood Spot in Laboratory: Directions and Prospects. *Diagnostics*, 10(4). doi:10.3390/diagnostics10040248

Mays, N., Pope, C., & Popay, J. (2005). Systematically Reviewing Qualitative and Quantitative Evidence to Inform Management and Policy-Making in the Health Field. *Journal of Health Services Research & Policy*, 10(Supplement 1), 6-20.

McArdle, A. J., Turkova, A., & Cunningham, A. J. (2018). When do Co-Infections Matter? *Current Opinion in Infectious Diseases*, 31(3), 209-215. doi:10.1097/QCO.0000000000000447

McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016). PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical Epidemiology*, 75, 40-46. doi:10.1016/j.jclinepi.2016.01.021

Miesse, P. K., Collier, B. B., & Grant, R. P. (2022). Monitoring of SARS-CoV-2 Antibodies Using Dried Blood Spot for At-Home Collection. *Scientific Reports*, 12(1), 5812. doi:10.1038/s41598-022-09699-4



- Mwau, M., Danda, J., Mbugua, J., Handa, A., Fortunko, J., Worlock, A., & Nair, S. V. (2021). Prospective Evaluation of Accuracy of HIV Viral Load Monitoring Using the Aptima HIV Quant Dx Assay with Fingerstick and Venous Dried Blood Spots Prepared Under Field Conditions in Kenya. *PLoS ONE*, 16(4), e0249376. doi:10.1371/journal.pone.0249376
- Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., . . . Moher, D. (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *BMJ*, 372, n71. doi:10.1136/bmj.n71
- Prinsenber, T., Rebers, S., Boyd, A., Zuure, F., Prins, M., van der Valk, M., & Schinkel, J. (2020). Dried Blood Spot Self-Sampling at Home is a Feasible Technique for Hepatitis C RNA Detection. *PLoS ONE*, 15(4), e0231385. doi:10.1371/journal.pone.0231385
- Roberts, C. P., & Klausner, J. D. (2016). Global Challenges in Human Immunodeficiency Virus and Syphilis Co-Infection Among Men Who Have Sex With Men. *Expert Review of Anti-Infective Therapy*, 14(11), 1037-1046. doi:10.1080/14787210.2016.1236683
- Rutstein, S. E., Kamwendo, D., Lugali, L., Thengolose, I., Tegha, G., Fiscus, S. A., . . . Mataya, R. (2014). Measures of Viral Load Using Abbott RealTime HIV-1 Assay on Venous and Fingerstick Dried Blood Spots from Provider-Collected Specimens in Malawian District Hospitals. *Journal of Clinical Virology*, 60(4), 392-398. doi:10.1016/j.jcv.2014.05.005
- Saludes, V., Folch, C., Morales-Carmona, A., Ferrer, L., Fernandez-Lopez, L., Munoz, R., . . . Martro, E. (2018). Community-Based Screening of Hepatitis C with a One-Step RNA Detection Algorithm from Dried-Blood Spots: Analysis of Key Populations in Barcelona, Spain. *Journal of Viral Hepatitis*, 25(3), 236-244. doi:10.1111/jvh.12809
- Shayan, S. J., Nazari, R., & Kiwanuka, F. (2021). Prevalence of HIV and HCV Among Injecting Drug Users in Three Selected WHO-EMRO Countries: A Meta-Analysis. *Harm Reduction Journal*, 18(1), 59. doi:10.1186/s12954-021-00505-4
- Sherman, G. G., Stevens, G., Jones, S. A., Horsfield, P., & Stevens, W. S. (2005). Dried Blood Spots Improve Access to HIV Diagnosis and Care for Infants in Low-Resource Settings. *Journal of Acquired Immune Deficiency Syndromes*, 38(5), 615-617.

Taieb, F., Tran Hong, T., Ho, H. T., Nguyen Thanh, B., Pham Phuong, T., Viet Ta, D., . . . Madec, Y. (2018). First Field Evaluation of the Pptimized CE Marked Abbott Protocol for HIV RNA Testing on Dried Blood Spot in a Routine Clinical Setting in Vietnam. *PLoS ONE*, 13(2), e0191920. doi:10.1371/journal.pone.0191920

Takano, M., Iwahashi, K., Satoh, I., Araki, J., Kinami, T., Ikushima, Y., . . . Group, H. I. V. C. S. (2018). Assessment of HIV Prevalence Among MSM in Tokyo Using Self-Collected Dried Blood Spots Delivered Through the Postal Service. *BMC Infectious Diseases*, 18(1), 627. doi:10.1186/s12879-018-3491-0

Tran, T. H., Nguyen, B. T., Nguyen, T. A., Pham, T. T. P., Nguyen, T. T. T., Mai, H. T. B., . . . Madec, Y. (2020). Dried Blood Spots Perform Well to Identify Patients with Active HCV Infection in Vietnam. *Journal of Viral Hepatitis*, 27(5), 514-519. doi:10.1111/jvh.13263

Tuaillon, E., Mondain, A. M., Meroueh, F., Ottomani, L., Picot, M. C., Nagot, N., . . . Ducos, J. (2010). Dried blood spot for hepatitis C virus serology and molecular testing. *Hepatology*, 51(3), 752-758. doi:10.1002/hep.23407

UNAIDS. (2014). *Fast-Track: Ending the AIDS Epidemic by 2030*. Retrieved from Geneva, Switzerland:

Vetter, B. N., Reipold, E. I., Ongarello, S., Fajardo, E., Tyshkovskiy, A., Ben, I., & Vasylyev, M. (2021). Prospective Evaluation of Hepatitis C Virus Antibody Detection in Whole Blood Collected on Dried Blood Spots with the INNOTEST HCV Ab IV Enzyme Immunoassay. *Journal of Clinical Virology*, 137, 104783. doi:10.1016/j.jcv.2021.104783

Villar, L. M., de Oliveira, J. C., Cruz, H. M., Yoshida, C. F., Lampe, E., & Lewis-Ximenez, L. L. (2011). Assessment of Dried Blood Spot Samples as a Simple Method for Detection of Hepatitis B Virus Markers. *Journal of Medical Virology*, 83(9), 1522-1529. doi:10.1002/jmv.22138

Vojnov, L., Carmona, S., Zeh, C., Markby, J., Boeras, D., Prescott, M. R., . . . Consortium, D. B. S. f. V. D. I. (2022). The Performance of Using Dried Blood Spot Specimens for HIV-1 Viral Load Testing: A Systematic Review and Meta-Analysis. *PLoS Medicine*, 19(8), e1004076. doi:10.1371/journal.pmed.1004076

Whiting, P. F., Weswood, M. E., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. N., & Kleijnen, J. (2006). Evaluation of QUADAS, A Tool for the Quality Assessment of Diagnostic Accuracy Studies. *BMC Medical Research Methodology*, 6(9). doi:10.1186/1471-2288-6-9

Wong, M. P., Meas, M. A., Adams, C., Hernandez, S., Green, V., Montoya, M., . . . Harris, E. (2022). Development and Implementation of Dried Blood Spot - Based COVID-19 Serological Assays for Epidemiologic Studies. *Microbiology Spectrum*, 10(3), e0247121.

Young, J., Ablona, A., Klassen, B. J., Higgins, R., Kim, J., Lavoie, S., . . . Lachowsky, N. J. (2022). Implementing Community-Based Dried Blood Spot (DBS) Testing for HIV and Hepatitis C: A Qualitative Analysis of Key Facilitators and Ongoing Challenges. *BMC Public Health*, 22(1), 1085. doi:10.1186/s12889-022-13525-x

# **Figure 1**

*PRISMA flow diagram*




Figure 2

Proportion of reported performance measurements with <50%, 50-89%, or ≥90% sensitivity, specificity, negative predictive values (NPV), and positive predictive values (PPV)





Figure 3

452 Proportion of studies with low, high, or unclear risk of bias and concerns regarding applicability based on the QUADAS-2 tool



453

454

455 **Table 1**

456

457 *Studies reporting limit of detection and/or limit of quantification with DBS specimens*

458

Study	Index Test	STBBI	LOD	LOQ	Notes
(Aitken et al., 2013)	In-house RT-qPCR	HIV	1,000 copies/mL	NR	DBS stored at ambient temperature (2 to 192 days)
	In-house RT-qPCR	HIV	1,000 copies/mL	NR	DBS stored at -20°C (45 to 112 days)
	In-house RT-qPCR	HIV	1,000 copies/mL	NR	DBS stored at -70°C (270 to 515 days)
(Patricia Alvarez et al., 2015)	COBAS AmpliPrep/TaqMan HIV-1 Quantitative Test v2.0 (Roche)	HIV	400 copies/mL	NR	Mothers and infants (ART naïve)
	COBAS AmpliPrep/TaqMan HIV-1 Quantitative Test v2.0 (Roche)	HIV	400 copies/mL	NR	Mothers and infants (on ART)
	COBAS AmpliPrep/TaqMan HIV-1 Quantitative Test v2.0 (Roche)	HIV	400 copies/mL	NR	Mothers and infants (all)
	Versant HIV-1 RNA 1.0 (Siemens)	HIV	~880 copies/mL	NR	Mothers and infants (ART naïve)
	Versant HIV-1 RNA 1.0 (Siemens)	HIV	~880 copies/mL	NR	Mothers and infants (on ART)
	Versant HIV-1 RNA 1.0 (Siemens)	HIV	~880 copies/mL	NR	Mothers and infants (all)
(Andreotti et al., 2010)	COBAS TaqMan RT-qPCR (Roche)	HIV	313 copies/mL	NR	Pregnant women (ART naïve)
	COBAS TaqMan RT-qPCR (Roche)	HIV	313 copies/mL	NR	Pregnant women (on ART)
(Choudhary et al., 2013)	In-house PCR	HIV	1,300 CEM cells	NR	HIV-1 proviral test
(Erba et al., 2015)	m2000sp, m2000rt (Abbott)	HIV	616 copies/mL	NR	(Erba et al., 2015)
(Fiscus, Brambilla, Grosso, Schock, & Cronin, 1998)	NASBA HIV-1 QT (Organon Teknika)	HIV	1,000 copies/mL	NR	
(Huang, Erickson, Mak, Salituro, & Abravaya, 2011)	RealTime HIV-1 Qualitative Assay (Abbott)	HIV	2,469 copies/mL	NR	DBS prepared with material from the Virology Quality Assurance Laboratory (AIDS Clinical Trial Group)
	RealTime HIV-1 Qualitative Assay (Abbott)	HIV	3,085 copies/mL	NR	DBS prepared from the WHO 2 <sup>nd</sup> International

					Standard
(Kane et al., 2008)	NucliSENS HIV-1 EasyQ (bioMérieux)	HIV	870 IU/mL	NR	
(Marconi et al., 2009)	m2000sp, m2000rt (Abbott)	HIV	200 – 1,000 copies/mL	NR	
(Nugent et al., 2009)	Aptima HIV-1 RNA Qualitative Assay (Gen-Probe)	HIV	2,384 copies/mL	NR	
(Tang et al., 2017)	m2000 RealTime HIV-1 RNA (Abbott)	HIV	839 copies/mL	839 copies/mL	
(Templer et al., 2016)	TaqMan HIV-1 v2.0 (Roche)	HIV	221.8 copies/mL	NR	
	TaqMan HIV-1 v1.0 (Roche)	HIV	1,090 copies/mL	NR	
	RealTime HIV-1 Qualitative (Abbott)	HIV	2,500 copies/mL	NR	
(van Deursen et al., 2010)	NucliSENS EasyQ HIV-1 v2.0 (bioMérieux)	HIV	800 copies/mL	NR	
(Viljoen et al., 2010)	Generic HIV Viral Load (Biocentric)	HIV	3,100 copies/mL	NR	Durban (infants)
	Generic HIV Viral Load (Biocentric)	HIV	1,550 copies/mL	NR	Bobo-Dioulasso (mothers and infants)
(Zeh et al., 2017)	m2000 RealTime HIV-1 RNA (Abbott)	HIV	1,222 copies/mL	NR	
(Fajardo et al., 2014)	NucliSENS EasyQ HIV-1 v2.0 (bioMérieux)	HIV	NR	100 copies/mL	
(Mavedzenge et al., 2015)	NucliSENS EasyQ HIV-1 v2.0 (bioMérieux)	HIV	NR	100 copies/mL	
(Bennett et al., 2012)	In-house RT-qPCR	HCV	250 IU/mL	NR	
(Catlett et al., 2019)	Aptima HCV Quant DX (Hologic)	HCV	13 IU/mL	525 IU/mL	
(De Crignis et al., 2010)	In-house RT-qPCR	HCV	2,500 copies/mL	NR	
(Mahajan, Choudhary, Kumar, & Gupta, 2018)	m2000rt HCV (Abbott)	HCV	1,000 IU/mL	NR	
(B. L. C. Marques et al., 2016)	In-house RT-qPCR	HCV	58.5 copies/mL	NR	
(Nguyen et al., 2018)	Generic HCV Assay (Biocentric)	HCV	3,000 IU/mL	NR	
(Vazquez-Moron et al., 2018)	In-house RT-qPCR	HCV	5,000 copies/mL	NR	
(Weber, Sahoo, Taylor, Shi, & Pinsky, 2019)	Aptima HCV Quant DX (Hologic)	HCV	267 IU/mL	NR	
(Parr et al., 2018)	m2000 RealTime HCV	HCV	1,196 IU/mL	NR	6 mm DBS



	Viral Load (Abbott)				punches
	m2000 RealTime HCV Viral Load (Abbott)	HCV	494 IU/mL	NR	12 mm DBS punches
(Santos et al., 2012)	In-house RT-qPCR	HCV	50 IU/mL	NR	
(Shepherd, Baxter, & Gunson, 2019)	m2000 RealTime HCV Viral Load (Abbott)	HCV	178 – 1,779 IU/mL	NR	
(Solmone et al., 2002)	In-house RT-qPCR	HCV	960 IU/mL	NR	
(Saludes et al., 2018)	In-house RT-qPCR	HCV	541 UI/mL	NR	
(Stene-Johansen et al., 2016)	In-house qPCR	HBV	501.19 IU/mL	NR	
(Jardi et al., 2004)	In-house qPCR	HBV	2,000 copies/mL	NR	
(Mohamed et al., 2013)	Chemiluminescent microparticle immunoassay (Abbott)	HBV	0.30 ± 0.08 IU/mL	NR	HBAg
	Chemiluminescent microparticle immunoassay (Abbott)	HBV	18.11 ± 6.05 IU/mL	NR	Anti-HBs
	AmpliPrep/COBAS TaqMan HBV Test v2.0 (Roche)	HBV	914.1 ± 157.8 IU/mL	NR	HBV DNA
(Vinikoor et al., 2015)	AmpliPrep/COBAS TaqMan HBV v2.0 (Roche)	HBV	1,000 IU/mL	NR	
(Wilson P., 2018)	ARCHITECT Qualitative HBsAg Assay (Abbott)	HBV	0.75 IU/mL	NR	
(Lira et al., 2009)	HBV Monitor COBAS Amplicor v1.5 (Roche)	HBV	2,000 copies/mL	NR	
(Zhang & Wang, 2010)	In-house PCR	HBV	5 copies/mL	NR	
(Jackson et al., 2022)	RealTime HBV Viral Load (Abbott)	HBV	389 IU/mL	NR	
(Roger et al., 2020)	Aptima HBV Quant DX (Hologic)	HBV	445 IU/mL	NR	
(Shimakawa et al., 2021)	LUMIPULSE CLEIA (Fujirebio)	HBV	19,115 IU/mL	NR	HBV core-related antigen
(Bezerra et al., 2022)	In-house qPCR	HBV	852.5 copies/mL	NR	
(Bezerra, Portilho, Frota, & Villar, 2021)	In-house qPCR	HBV	20 copies/mL	NR	High Pure Viral Nucleic Acid Kit (Roche)
(Bezerra et al., 2021)	In-house PCR	HBV	2,000 copies/mL	NR	QIAamp DNA Blood Mini Kit (Qiagen)
	In-house PCR	HBV	2,000 copies/mL	NR	Invisorb Spin Blood Midi Kit (Invitek)
	In-house PCR	HBV	20,000	NR	DBS Genomic

			copies/mL		DNA Isolation Kit (Norgen Biotek)
(Bargain, Heslan, Thibault, & Pronier, 2020)	GeneXpert HBV (Cepheid)	HBV	NR	400 IU/mL	
(Noda, Eizuru, Minamishima, Ikenoue, & Mori, 1993)	In-house PCR	HTLV	Single HUT102 cell	NR	

ART = antiretroviral therapy; DBS = dried blood spot; IU/mL = international units/mL; LOD = limit of detection; LOQ = limit of quantification; NR = not reported; STBBI = sexually transmitted and blood-borne infection

**Table 2**

*Studies reporting test performance according to test cut-off values*

Study	STBBI	Index Test	Cut-Off	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Notes
(García-Cisneros et al., 2019)	HSV-2	IgG-G2 Human (Human Diagnostics)	≥1.15 <sup>a</sup>	99.7 (98.3-100.0)	4.5 (3.0-6.5)	37.3 (34.1-40.6)	96.3 (81.0-99.9)	
			≥4.61 <sup>b</sup>	90.4 (84.4-94.4)	87.1 (81.2-91.4)	84.7 (77.9-89.8)	92.0 (86.7-95.4)	
(Villar et al., 2011)	HBV	ETI-AB-COREK Plus (DiaSorin)	Mean of 3 calibrator scores x 0.3 <sup>a</sup>	89.2 (79.8-95.2)	97.5 (91.4-99.7)	97.1 (89.8-99.6)	90.8 (82.7-96.0)	
			≤0.951 <sup>b</sup>	100.0 (95.1-100.0)	2.5 (0.3-8.6)	48.4 (40.2-56.6)	100.0 (15.8-100.0)	
			≤0.261 <sup>b</sup>	90.5 (81.5-96.1)	92.6 (84.6-97.2)	91.8 (83.0-96.9)	91.5 (83.2-96.5)	
		ETI-AB-AUK-3 (DiaSorin)	Mean of kit calibrator 1 <sup>a</sup>	83.1 (71.0-91.6)	81.3 (70.7-89.4)	77.8 (65.5-87.3)	85.9 (75.6-93.0)	
			>0.119 <sup>b</sup>	66.1 (52.6-77.6)	98.7 (92.8-100.0)	97.5 (86.8-99.9)	78.7 (69.1-86.5)	
			>0.095 <sup>b</sup>	78.0 (65.3-87.7)	97.3 (90.7-99.7)	95.8 (85.8-99.5)	84.9 (75.5-91.7)	
		ETI-MAK-4 (DiaSorin)	Mean of negative control + 0.03 <sup>a</sup>	95.5 (84.5-99.4)	70.8 (60.2-80.0)	61.8 (49.2-73.3)	96.9 (89.3-99.6)	
			>0.100 <sup>b</sup>	93.2	98.9	97.6	96.7	

				(81.3-98.6)	(93.9-100.0)	(87.4-99.9)	(90.7-99.3)	
			>0.115 <sup>b</sup>	97.6 (87.4-99.9)	96.7 (90.7-99.3)	93.2 (81.3-98.6)	98.9 (93.9-100.0)	
(Catlett et al., 2019)		Aptima HCV Quant Dx (Hologic)	Detected	96.4 (89.8-99.3)	95.8 (78.9-99.9)	NR	NR	
			≥15 IU/mL	95.1 (88.0-98.7)	96.0 (79.7-99.9)	NR	NR	
			≥1,000 IU/mL	100.0 (95.3-100.0)	100.0 (88.4-100.0)	NR	NR	
(Brandão et al., 2013)	HCV	Monolisa HCV AgAb ULTRA EIA (Bio-Rad)	Not specified <sup>a</sup>	95.0 (83.1-99.4)	100.0 (98.9-100.0)	100.0 (90.8-100.0)	99.4 (97.9-99.9)	
			0.108 <sup>b</sup>	97.5 (86.8-99.9)	97.2 (94.9-98.6)	79.6 (65.7-89.8)	99.7 (98.4-99.0)	
			0.287 <sup>b</sup>	97.5 (86.8-99.9)	99.7 (98.4-100.0)	100.0 (91.0-100.0)	100.0 (99.0-100.0)	
		Murex HCV AgAb Combination EIA (DiaSorin)	Not specified <sup>a</sup>	82.5 (67.2-92.7)	98.0 (95.9-99.2)	82.5 (67.2-92.7)	98.0 (95.9-99.2)	
			0.514 <sup>b</sup>	80.0 (64.3-90.9)	99.4 (97.9-99.9)	94.1 (80.3-99.3)	97.7 (95.6-99.0)	
			0.239 <sup>b</sup>	97.5 (86.8-99.9)	96.0 (93.3-97.8)	73.6 (93.3-97.8)	100 (98.3-100.0)	
(Erba et al., 2015)	HIV	m2000SP, m2000RT (Abbott)	≥40 copies/mL	74.0 (66.9-80.3)	99.0 (94.5-99.8)	99.2 (95.8-99.9)	68.3 (60.0-75.8)	
			≥1,000 copies/mL	94.2 (88.9-97.5)	98.6 (94.9-99.8)	98.5 (94.6-99.8)	94.5 (89.4-97.6)	
(Fajardo et al., 2014)	HIV	NucliSENS EasyQ HIV-1 v2.0 (bioMérieux)	≥1,000 copies/mL	88.7 (81.1-94.0)	97.8 (96.1-98.9)	NR	NR	DBS prepared from capillary blood (finger pokes)
			≥3,000 copies/mL	84.9	99.8	NR	NR	DBS prepared

				(76.0-91.5)	(98.9-100.0)			from capillary blood (finger pokes)
			≥5,000 copies/mL	83.0 (73.4-90.1)	100.0 (99.3-100.0)	NR	NR	DBS prepared from capillary blood (finger pokes)
			≥1,000 copies/mL	91.4 (84.4-96.0)	97.2 (95.4-98.5)	NR	NR	DBS prepared from venous blood
			≥3,000 copies/mL	90.0 (82.2-95.4)	99.4 (98.3-99.9)	NR	NR	DBS prepared from venous blood
			≥5,000 copies/mL	88.5 (79.9-94.3)	99.8 (98.9-100.0)	NR	NR	DBS prepared from venous blood
(Guichet et al., 2018)	HIV	In-house RT-qPCR	≥1,000 copies/mL	90.0 (83.0-96.0)	49.0 (37.0-61.0)	NR	NR	NucliSENS (bioMérieux)
			≥5,000 copies/mL	74.0 (62-86.0)	77.0 (69.0-85.0)	NR	NR	NucliSENS (bioMérieux)
			≥1,000 copies/mL	80.0 (71.0-89.0)	59.0 (47.0-71.0)	NR	NR	m2000SP (Abbott)
			≥5,000 copies/mL	79.0 (68.0-90.0)	68.0 (59.0-72.0)	NR	NR	m2000SP (Abbott)
			≥1,000 copies/mL	80.0 (71.0-89.0)	100.0 (100.0-100.0)	NR	NR	NucliSENS (bioMérieux), Turbo DNase-Free (Ambion)
			≥5,000 copies/mL	23.0 (12.0-34.0)	100.0 (100.0-100.0)	NR	NR	NucliSENS (bioMérieux), Turbo DNase-Free (Ambion)
			≥1,000 copies/mL	27.0 (17.0-37.0)	81.0 (70.0-90.0)	NR	NR	NucliSENS (bioMérieux), HL-dsDNase (TATAA Biocenter AB)
			≥5,000 copies/mL	51.0 (37.0-65.0)	92.0 (86.0-97.0)	NR	NR	NucliSENS (bioMérieux), HL-dsDNase (TATAA

								Biocenter AB)
			≥1,000 copies/mL	60.0 (49.0-71.0)	82.0 (73.0-91.0)	NR	NR	NucliSENS (bioMérieux), FVE protocol
			≥5,000 copies/mL	49.0 (35.0-62.0)	99.0 (97.0-100.0)	NR	NR	NucliSENS (bioMérieux), FVE protocol
			≥1,000 copies/mL	83.0 (75.0-91.0)	58.0 (46.0-70.0)	NR	NR	m2000SP, m2000RT (Abbott)
			≥5,000 copies/mL	75.0 (63.0-87.0)	89.0 (83.0-95.0)	NR	NR	m2000SP, m2000RT (Abbott)
(Halfon et al., 2012)	HBV	HBV COBAS TaqMan (Roche)	≥1,400 IU/mL	98.0 (95.0-100.0)	100.0 (100.0-100.0)	NR	NR	
			≥2,000 IU/mL	91.0 (85.0-97.0)	100.0 (100.0-100.0)	NR	NR	
(Hobbs et al., 2017)	HSV-2	Kalon HSV-2 ELISA (Kalon Biological Ltd)	>1.1 <sup>a</sup>	98.8 (92.7-99.9)	98.9 (93.4-99.9)	NR	NR	
			>1.5 <sup>b</sup>	98.8 (93.6-99.8)	98.9 (94.2-99.8)	NR	NR	
(Judd et al., 2003)	HCV	Ortho HCV 3.0 (Bio-Rad)	0.100 <sup>a</sup>	99.2	100.0			
			Negative mean + 1 SD <sup>b</sup>	100.0	92.4	NR	NR	
			Negative mean + 2 SD <sup>b</sup>	100.0	96.9	NR	NR	
			Negative mean + 3 SD <sup>b</sup>	99.6	99.7	NR	NR	
			Negative mean + 4 SD <sup>b</sup>	99.6	99.7	NR	NR	
			Negative mean + 5 SD <sup>b</sup>	99.6	100.0	NR	NR	
			Negative mean + 6 SD <sup>b</sup>	99.2	100.0	NR	NR	
(Makadzang et al., 2017)	HIV	COBAS AmpliPrep/COBAS TaqMan (Roche)	Detected	77.0 (69.4-85.5)	100.0 (97.1-100.0)	100.0 (96.8-100.0)	78.5 (71.2-84.6)	

			≥1,000 copies/mL	92.7 (88.6-96.6)	100.0 (97.6-100.0)	100.0 (96.8-100.0)	94.3 (89.5-97.4)	
			≥5,000 copies/mL	70.9 (61.8-79.0)	100.0 (97.6-100.0)	100.0 (95.7-100.0)	82.0 (75.8-87.2)	
(B. L. Marques et al., 2012)	HCV	ETI-AB-HCVK-4 (DiaSorin)	0.592 <sup>a</sup>	88.9 (76.0-96.3)	96.1 (93.6-97.9)	74.1 (60.4-85.0)	98.6 (96.7-99.5)	
			0.648 <sup>b</sup>	88.9 (76.0-96.3)	96.4 (93.9-98.1)	75.5 (61.7-86.2)	98.6 (96.7-99.5)	
			1.345 <sup>b</sup>	88.9 (76.0-96.3)	98.6 (96.8-99.6)	88.9 (76.0-96.3)	98.6 (96.8-99.6)	
		HCV Ab (Radim)	0.347 <sup>a</sup>	97.5 (86.8-99.9)	99.5 (98.1-99.9)	95.1 (83.5-99.4)	99.7 (98.5-100.0)	
			0.351 <sup>b</sup>	97.5 (86.8-99.9)	99.5 (98.1-99.9)	95.1 (83.5-99.4)	99.7 (98.5-100.0)	
			0.284 <sup>b</sup>	97.5 (86.8-99.9)	99.2 (97.7-99.8)	92.9 (80.5-98.5)	99.7 (98.5-100.0)	
(McCarron et al., 1999)	HCV	Monolisa anti-HCV (Sanofi Pasteur)	>0.99 <sup>b</sup>	100.0	87.5	NR	NR	
			>1.99 <sup>b</sup>	97.2	100.0	NR	NR	
(Neogi et al., 2012)	HIV	m2000RT, m2000SP (Abbott)	2.17 to 3 log <sup>10</sup> copies/mL	50.0	100.0	NR	NR	
			>3 to 3.7 log <sup>10</sup> copies/mL	90.0	100.0	NR	NR	
			>3.7 log <sup>10</sup> copies/mL	100.0	100.0	NR	NR	
(Nugent et al., 2009)	HIV	Aptima HIV-1 RNA Qualitative Assay (Gen-Probe)	≥500 copies/mL	65.0	NR	NR	NR	
			≥2,500 copies/mL	92.0	NR	NR	NR	
			≥5,000 copies/mL	100	NR	NR	NR	
			≥10,000 copies/mL	100	NR	NR	NR	

(Pannus et al., 2013)	HIV	NucliSENS EasyQ v2.0 (bioMérieux)	≥1,000 copies/mL	78.6 (59.0-91.7)	100.0 (98.9-100.0)	100.0 (84.6-100.0)	98.2 (96.1-99.3)	DBS prepared from capillary blood (finger pokes)
			≥1,000 copies/mL	89.3 (71.8-97.7)	99.7 (98.3-100.0)	96.2 (80.4-99.9)	99.1 (97.3-99.8)	DBS prepared from venous blood
			≥5,000 copies/mL	69.6 (47.1-86.8)	100.0 (89.9-100.0)	100.0 (79.4-100.0)	97.9 (95.7-99.2)	DBS prepared from capillary blood (finger pokes)
			≥5,000 copies/mL	60.9 (38.5-80.3)	100.0 (98.9-100.0)	100.0 (76.8-100.0)	97.3 (95.0-98.8)	DBS prepared from venous blood)
(Pirillo et al., 2011)	HIV	VERSANT HIV-1 RNA 1.0 (Siemens)	≥37 copies/mL	88.2 (79.4-93.6)	69.2 (42.0-87.4)	94.9 (90.1-99.8)	47.4 (24.9-69.8)	
			≥5,000 copies/mL	85.1 (76.5-88.6)	96.1 (88.2-99.3)	95.2 (85.6-99.1)	87.5 (80.3-90.4)	
(Pollack et al., 2018)	HIV	COBAS AmpliPrep/COBAS TaqMan (Roche)	≥1,000 copies/mL	98.8 (93.3-100.0)	74.3 (70.8-77.5)	31.5 (25.8-37.6)	99.8 (98.9-100.0)	Guanidinium pre-extraction
			≥5,000 copies/mL	92.4 (84.2-97.2)	97.9 (96.6-98.9)	83.9 (74.5-90.9)	99.1 (98.1-99.7)	Guanidinium pre-extraction
			≥1,000 copies/mL	95.1 (87.8-98.6)	98.8 (97.7-99.5)	90.6 (82.3-95.8)	99.4 (98.5-99.8)	Correction factor applied (0.3 log <sup>10</sup> copies/mL)
			≥5,000 copies/mL	96.3 (89.6-99.2)	98.2 (96.9-99.1)	86.7 (77.9-92.9)	99.6 (98.7-99.9)	Correction factor applied (0.3 log <sup>10</sup> copies/mL)
			≥1,000 copies/mL	65.8 (54.3-76.1)	100.0 (99.5-100.0)	100.0 (93.2-100.0)	96.2 (94.5-97.5)	Correction factor applied (0.7 log <sup>10</sup> copies/mL)
			≥5,000 copies/mL	84.8 (75.0-91.9)	99.7 (98.9-100.0)	97.1 (89.9-99.6)	98.3 (97.0-99.1)	Correction factor applied (0.7

								log <sup>10</sup> copies/mL)
(Rutstein et al., 2014)	HIV	m2000RT, m2000SP (Abbott)	≥1,000 copies/mL	100.0	97.1	75.0	100.0	DBS prepared from venous blood
			≥1,000 copies/mL	100.0	94.9	63.2	100.0	DBS prepared from capillary blood (finger pokes)
			≥5,000 copies/mL	100.0	98.6	83.3	100.0	DBS prepared from venous blood
			≥5,000 copies/mL	100.0	97.8	76.9	100.0	DBS prepared from capillary blood (finger pokes)
(Sawadogo et al., 2014)	HIV	COBAS AmpliPrep/COBAS TaqMan (Roche)	≥1,000 copies/mL	99.0 (97.0-100.0)	26.0 (22.0-29.0)	29.0 (26.0-33.0)	99.0 (96.0-100.0)	
			≥5,000 copies/mL	99.0 (96.0-100.0)	55.0 (51.0-59.0)	33.0 (29.0-37.0)	100.0 (98.0-100.0)	
(Schmitz et al., 2017)	HIV	COBAS AmpliPrep/COBAS TaqMan (Roche)	≥1,000 copies/mL	90.1 (85.7-93.6)	93.1 (90.6-95.2)	NR	NR	DBS prepared from venous blood
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥1,000 copies/mL	90.3 (85.7-93.7)	94.9 (92.6-96.6)	NR	NR	DBS prepared from capillary blood (microtainer)
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥1,000 copies/mL	88.1 (83.3-92.0)	94.5 (92.1-96.3)	NR	NR	DBS prepared from capillary blood (finger pokes)
		RealTime HIV-1 (Abbott)	≥1,000 copies/mL	94.4 (90.6-97.0)	33.0 (28.9-37.3)	NR	NR	DBS prepared from venous blood
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥3,000 copies/mL	85.2 (80.1-89.4)	98.0 (96.4-99.1)	NR	NR	DBS prepared



		S TaqMan (Roche)						from venous blood
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥3,000 copies/mL	88.1 (83.3-92.0)	97.6 (95.9-98.8)	NR	NR	DBS prepared from capillary blood (microtainer)
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥3,000 copies/mL	85.2 (80.0-89.4)	97.8 (96.2-98.9)	NR	NR	DBS prepared from capillary blood (finger pokes)
		RealTime HIV-1 (Abbott)	≥3,000 copies/mL	88.4 (83.5-92.2)	60.9 (56.6-65.2)	NR	NR	DBS prepared from venous blood
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥5,000 copies/mL	83.1 (77.8-87.6)	98.4 (96.9-99.3)	NR	NR	DBS prepared from venous blood
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥5,000 copies/mL	83.9 (78.6-88.3)	98.6 (97.2-99.4)	NR	NR	DBS prepared from capillary blood (microtainer)
		COBAS AmpliPrep/COBAS TaqMan (Roche)	≥5,000 copies/mL	82.2 (76.7-86.9)	98.8 (97.4-99.6)	NR	NR	DBS prepared from capillary blood (finger pokes)
		RealTime HIV-1 (Abbott)	≥5,000 copies/mL	79.7 (74.0-84.7)	77.0 (73.1-80.5)	NR	NR	DBS prepared from venous blood
(Taieb et al., 2018)	HIV	m2000SP, m2000RT (Abbott)	Detected	95.8 (88.1-99.1)	63.6 (54.8-71.8)	NR	NR	
			≥839 copies/mL	91.5 (82.5-96.8)	95.5 (90.3-98.3)	NR	NR	
			≥1,000 copies/mL	90.1 (80.7-95.9)	96.2 (91.4-98.8)	NR	NR	
			≥3,000 copies/mL	84.5 (74.0-92.0)	99.2 (95.9-100.0)	NR	NR	
			≥5,000 copies/mL	80.3 (69.1-88.8)	100.0 (97.2-100.0)	NR	NR	
(Taieb et al.,	HIV	COBAS	≥1,000	54.9	100.0	NR	NR	

2016)		AmpliPrep/COBAS TaqMan HIV-1 v2.0 (Roche)	copies/mL	(40.3-68.9)	(97.5-100.0)			
			≥3,000 copies/mL	45.2 (29.8-61.3)	100.0 (97.7-100.0)	NR	NR	
			≥5,000 copies/mL	47.5 (31.5-63.8)	100.0 (97.7-100.0)	NR	NR	
		Real-Time HIV-1 (Abbott)	≥1,000 copies/mL	93.3 (81.7-98.6)	94.8 (90.0-97.7)	NR	NR	
			≥3,000 copies/mL	97.4 (86.2-99.9)	96.3 (92.0-98.6)	NR	NR	
			≥5,000 copies/mL	100 (90.5-100.0)	98.8 (95.6-99.8)	NR	NR	
(Vidya et al., 2012)		m2000RT (Abbott)	≤1,000 copies/mL	62.0	NR	NR	NR	
			1,000-3,000 copies/mL	88.0	NR	NR	NR	
			>3,000 copies/mL	100.0	NR	NR	NR	
(Zeh et al., 2017)	HIV	COBAS AmpliPrep/COBAS TaqMan (Roche)	≥400 copies/mL	100.0 (97.6-100.0)	4.0 (0.5-13.7)	75.8 (69.2-81.6)	100.0 (15.8-100.0)	
			≥1,000 copies/mL	100.0	17.3	NR	NR	
			≥2,000 copies/mL	98.0	36.5	NR	NR	
			≥3,000 copies/mL	97.3	54.0	NR	NR	
			≥4,000 copies/mL	96.0	82.7	NR	NR	
			≥5,000 copies/mL	95.3	84.6	NR	NR	
		m2000RT (Abbott)	≥550 copies/mL	93.9 (88.8-97.2)	88.0 (82.2-92.4)	100.0 (97.4-100.0)	85.3 (73.8-93.0)	
			≥1,000 copies/mL	96.6	90.4	NR	NR	
			≥2,000 copies/mL	95.3	94.2	NR	NR	
			≥3,000 copies/mL	94.6	98.1	NR	NR	
			≥4,000 copies/mL	93.2	98.1	NR	NR	

			≥5,000 copies/mL	93.0	98.1	NR	NR	
(Biondi et al., 2019)	HCV	ARCHITECT Core Antigen (Abbott)	>3 fmol/L	94.1 (88.5-99.7)	NR	NR	NR	DBS stored at -80°C
			>10 fmol/L	85.3 (76.4-94.2)	NR	NR	NR	DBS stored at -80°C
			>3 fmol/L	94.1 (88.5-99.7)	NR	NR	NR	DBS stored at 4°C
			>10 fmol/L	85.3 (76.4-94.2)	NR	NR	NR	DBS stored at 4°C
			>3 fmol/L	91.2 (84.3-98.1)	NR	NR	NR	DBS stored at ambient °C
			>10 fmol/L	80.9 (70.8-91.0)	NR	NR	NR	DBS stored at ambient °C
			>3 fmol/L	92.7 (86.4-98.9)	NR	NR	NR	DBS stored at 37°C
			>10 fmol/L	80.9 (70.8-91.0)	NR	NR	NR	DBS stored at 37°C
			>3 fmol/L	92.7 (86.4-98.9)	NR	NR	NR	DBS stored at 37°C followed by 4°C
			>10 fmol/L	85.3 (76.4-94.2)	NR	NR	NR	DBS stored at 37°C followed by 4°C
(Catlett et al., 2019)	HCV	Aptima HCV Quant Dx (Hologic)	≥12 IU/mL	90.7 (80.0-97.0)	100.0 (97.0- 100.0)	NR	NR	
			≥1,000 IU/mL	92.5 (82.0-98.0)	100.0 (97.0- 100.0)	NR	NR	
			≥3,000 IU/mL	92.5 (92.0-98.0)	100.0 (97.0- 100.0)	NR	NR	
(Saludes et al., 2019)	HCV	In-house RT-qPCR	~12 IU/mL	88.3 (83.0-92.0)	NR	NR	NR	
			≥12 IU/mL	90.1 (85.0-93.5)	NR	NR	NR	
			≥1,000 copies/mL	96.1 (92.1-98.1)	NR	NR	NR	
			≥3,000 copies/mL	97.2	NR	NR	NR	

				(93.5-98.8)				
			≥50,000 copies/mL	100.0 (97.6-100.0)	NR	NR	NR	
(Saludes et al., 2020)	HCV	Xpert HCV VL Fingerstick (Cepheid)	~10 IU/mL	93.7 (84.8-97.5)	100.0 (90.1-100.0)	NR	NR	
			≥10 IU/mL	96.7 (88.8-99.1)	100.0 (90.1-100.0)	NR	NR	
			≥1,000 IU/mL	98.3 (91.1-99.7)	100.0 (90.1-100.0)	NR	NR	
			≥3,000 IU/mL	98.3 (91.0-99.7)	100.0 (90.1-100.0)	NR	NR	
(Tola et al., 2021)	HIV	m2000 RealTime HIV-1 (Abbott)	≥1,000 copies/mL	85.2 (81.1-89.3)	91.5 (88.7-94.3)	NR	NR	DBS prepared from capillary blood (microtainer)
			≥3,000 copies/mL	72.5 (67.3–77.7)	96.9 (95.2–98.6)	NR	NR	DBS prepared from capillary blood (microtainer)
			≥5,000 copies/mL	65.8 (60.3–71.4)	97.2 (95.5–98.8)	NR	NR	DBS prepared from capillary blood (microtainer)
			≥1,000 copies/mL	85.6 (81.5–89.6)	90.9 (88.1–93.8)	NR	NR	DBS prepared from capillary blood (finger pokes)
			≥3,000 copies/mL	71.5 (66.2–76.7)	96.6 (94.9–98.4)	NR	NR	DBS prepared from capillary blood (finger pokes)
			≥5,000	62.7	97.4	NR	NR	DBS

			copies/mL	(57.1–68.3)	(95.9–99.0)			prepared from capillary blood (finger pokes)
			≥1,000 copies/mL	89.1 (85.5–92.7)	86.6 (83.2–90.0)	NR	NR	DBS prepared from venous blood
			≥3,000 copies/mL	76.4 (71.5–81.3)	96.1 (94.2–98.1)	NR	NR	DBS prepared from venous blood
			≥5,000 copies/mL	67.2 (61.8–72.7)	96.6 (95.2–98.6)	NR	NR	DBS prepared from venous blood

<sup>a</sup>Manufacturer recommended

<sup>b</sup>Established in-house

NPV=negative predictive value; NR=not reported; PPV=positive predictive value; STBBI=sexually transmitted and blood-borne infection;

**Table 3**

*Studies comparing DBS prepared from venous and capillary blood*

Study	STBBI	Index Test	Preparation	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Notes
(Prinsen et al., 2020)	HCV	COBAS AmpliPrep/COBAS TaqMan (Roche)	Capillary (finger poke)	95.7 (78.1-99.9)	NR	NR	NR	
			Venous	96.4 (81.7-99.9)	NR	NR	NR	
	HIV		Capillary (finger poke)	100.0 (69.2-100.0)	NR	NR	NR	
			Venous	100.0 (73.5-100.0)	NR	NR	NR	
(Tran et al., 2020)	HCV	m2000SP, m2000RT (Abbott)	Capillary (finger poke)	98.6 (92.2-100.0)	NR	NR	NR	DBS stored at ambient °C (6-14 days)
			Venous	97.9 (92.7-99.7)	NR	NR	NR	
			Capillary	97.8	NR	NR	NR	DBS

			(finger poke)	(94.4-99.4)				stored at ambient °C (≥15 days)
			Venous	98.1 (94.4-99.6)	NR	NR	NR	
(Vetter et al., 2021)	HIV	INNOTEST HCV Ab IV (Fujirebio)	Capillary (finger poke)	100.0 (97.5-100.0)	100.0 (95.7-100.0)	NR	NR	
			Venous	100.0 (97.5-100.0)	100.0 (95.7-100.0)	NR	NR	
(Fajardo et al., 2014)	HIV	NudiSENS EasyQ HIV-1 v2.0 (bioMérieux)	Capillary (finger poke)	88.7 (81.1-94.0)	97.8 (96.1-98.9)	NR	NR	≥1,000 copies/mL
				84.9 (76.0-91.5)	99.8 (98.9-100.0)	NR	NR	≥3,000 copies/mL
				83.0 (73.4-90.1)	100.0 (99.3-100.0)	NR	NR	≥5,000 copies/mL
			Venous	91.4 (84.4-96.0)	97.2 (95.4-98.5)	NR	NR	≥1,000 copies/mL
				90.0 (82.2-95.4)	99.4 (98.3-99.9)	NR	NR	≥3,000 copies/mL
				88.5 (79.9-94.3)	99.8 (98.9-100.0)	NR	NR	≥5,000 copies/mL
(Mwau et al., 2021)	HIV	Aptima HIV-1 Quant Dx (Hologic)	Capillary (finger poke)	92.3 (87.0-95.5)	92.2 (85.3-96.0)	94.7 (90.0-97.3)	88.7 (81.2-93.4)	
			Venous	97.4 (93.6-99.0)	92.2 (85.3-96.0)	95.0 (90.4-97.4)	95.9 (90.0-98.4)	
(Rutstein et al., 2014)	HIV	m2000SP, m2000RT (Abbott)	Capillary (finger poke)	100	94.9	63.2	100	≥1,000 copies/mL
				100	97.8	76.9	100	≥5,000 copies/mL
			Venous	100	97.1	75.0	100	≥1,000 copies/mL
				100	98.6	83.3	100	≥5,000 copies/mL
(Schmitz et al., 2017)	HIV	COBAS AmpliPrep/COBA	Capillary (finger poke)	88.1 (83.3-92.0)	94.5 (92.1-96.3)	NR	NR	≥1,000 copies/mL

		S TaqMan v2.0 (Roche)						L
				85.2 (80.0-89.4)	97.8 (96.2-98.9)	NR	NR	≥3,000 copies/m L
				82.2 (76.7-86.9)	98.8 (97.4-99.6)	NR	NR	≥5,000 copies/m L
			Capillary (microtainer)	90.3 (85.7-93.7)	94.9 (92.6-96.6)	NR	NR	≥1,000 copies/m L
				88.1 (83.3-92.0)	97.6 (95.9-98.8)	NR	NR	≥3,000 copies/m L
				83.9 (78.6-88.3)	98.6 (97.2-99.4)	NR	NR	≥5,000 copies/m L
			Venous	90.1 (85.7-93.6)	93.1 (90.6-95.2)	NR	NR	≥1,000 copies/m L
				85.2 (80.1-89.4)	98.0 (96.4-99.1)	NR	NR	≥3,000 copies/m L
				83.1 (77.8-87.6)	98.4 (96.9-99.3)	NR	NR	≥5,000 copies/m L
(Tang et al., 2017)	HIV	m2000SP, m2000RT (Abbott)	Capillary (finger poke)	93.0 (88.7-95.2)	95.0 (92.0-97.4)	NR	NR	
				93.0 (85.3-97.1)	95.0 (90.9-97.6)	NR	NR	Analysis limited to people living with HIV currently receiving ART
			Venous	93.0 (89.6-95.8)	95.0 (91.0-96.8)	NR	NR	
				95.0 (87.1-97.9)	95.0 (90.9-97.6)	NR	NR	Analysis limited to people living with HIV currently receiving ART
(Tola et al., 2021)	HIV	m2000SP, m2000RT (Abbott)	Capillary (finger poke)	85.6 (81.5– 89.6)	90.9 (88.1– 93.8)	NR	NR	≥1,000 copies/m L
				71.5 (66.2–	96.6 (94.9–98.4	NR	NR	≥3,000 copies/m L

				76.7)				
				62.7 (57.1–68.3)	97.4 (95.9–99.0)	NR	NR	≥5,000 copies/m L
			Capillary (microtainer)	85.2 (81.1-89.3)	91.5 (88.7-94.3)	NR	NR	≥1,000 copies/m L
				72.5 (67.3– 77.7)	96.9 (95.2– 98.6)	NR	NR	≥3,000 copies/m L
				65.8 (60.3– 71.4)	97.2 (95.5– 98.8)	NR	NR	≥5,000 copies/m L
			Venous	89.1 (85.5– 92.7)	86.6 (83.2– 90.0)	NR	NR	≥1,000 copies/m L
				76.4 (71.5– 81.3)	96.1 (94.2– 98.1)	NR	NR	≥3,000 copies/m L
				67.2 (61.8– 72.7)	96.6 (95.2– 98.6)	NR	NR	≥5,000 copies/m L
(Kerschberge r et al., 2019)	HIV	COBAS AmpliPrep/COBA S TaqMan HIV-1 v2.0 (Roche)	Capillary (finger poke)	89.2 (79.1-95.6)	96.8 (94.0-98.5)	NR	NR	
			Venous (phlebotomist )	88.2 (78.1-94.8)	98.6 (96.5-99.6)	NR	NR	
			Venous (laboratory technician)	85.3 (74.6-92.7)	94.5 (91.3-96.8)	NR	NR	
		Biocentric	Capillary (finger poke)	87.1 (76.1-94.3)	95.4 (92.3-97.5)	NR	NR	
			Venous (phlebotomist )	87.7 (77.2-94.5)	97.6 (95.2-99.0)	NR	NR	
			Venous (laboratory technician)	89.2 (79.1-95.6)	94.6 (91.3-96.9)	NR	NR	
(Pannus et al., 2013)	HIV	NudiSENS Easy Q v2.0 (bioMérieux)	Capillary (finger poke)	78.6 (59.0-91.7)	100.0 (98.9- 100.0)	100.0 (84.6- 100.0 )	98.2 (96.1- 100.0 )	≥1,000 copies/m L
				69.6 (47.1-86.6)	100.0 (89.9- 100.0)	100.0 (79.4- 100.0)	97.9 (95.7- 99.2)	≥5,000 copies/m L



						)		
			Venous	89.3 (71.8-97.7)	99.7 (98.3-100.0)	96.2 (80.4-99.9)	99.1 (97.3-99.8)	≥1,000 copies/mL
				60.9 (38.5-80.3)	100.0 (98.9-100.0)	100.0 (76.8-100.0)	97.3 (95.0-98.8)	≥5,000 copies/mL
(Biondi et al., 2019)	HCV	ARCHITECT Core Antigen Assay (Abbott)	Capillary (finger poke)	91.8 (84.2-99.5)	NR	NR	NR	≥3 fmol/L; 1 spot (75 µL)
				81.6 (70.8-92.5)	NR	NR	NR	≥10 fmol/L; 1 spot (75 µL)
				93.9 (87.2-100.0)	NR	NR	NR	≥3 fmol/L; 2 spot (150 µL)
				85.7 (75.9-95.5)	NR	NR	NR	≥10 fmol/L; 2 spot (150 µL)
			Venous	91.8 (84.2-99.5)	NR	NR	NR	≥3 fmol/L; 1 spot (75 µL)
				87.8 (79.0-97.0)	NR	NR	NR	≥10 fmol/L; 1 spot (75 µL)
				93.9 (87.2-100.0)	NR	NR	NR	≥3 fmol/L; 2 spot (150 µL)
				87.8 (79.0-97.0)	NR	NR	NR	≥10 fmol/L; 2 spot (150 µL)

NPV=negative predictive value; NR=not reported; PPV=positive predictive value; STBBI=sexually transmitted and blood-borne infection;

**Table 4**

*Studies assessing test performance on DBS specimens collected from participants with co-infections*

Study	STBBI	Index Test	Participants	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Notes
(Flores, Cruz,	HCV	Murex AB (DiaSorin)	HIV +ve, HCV -ve	NA	100.0 (96.3-100.0)	NR	NR	

Marques, et al., 2017)								
			HIV -ve, HCV +ve	93.9 (90.0-96.6)	NA	NR	NR	
			HIV +ve, HCV -ve	NA	98.6 (95.1-99.8)	NR	NR	
			HIV +ve, HCV +ve	83.3 (69.7-92.5)	NA	NR	NR	
(Flores et al., 2021)	HBV	Elecsys HBsAg II (Roche)	Coagulopathy	100.0	100.0	100.0	100.0	
			Chronic kidney disease	100.0	99.6	92.9	100.0	
			HIV +ve	85.0	94.7	81.0	95.9	
		Elecsys anti-HBc II (Roche)	Coagulopathy	81.3	100.0	100.0	92.1	
			Chronic kidney disease	79.6	97.1	94.7	87.8	
			HIV+ve	97.2	88.9	85.4	98.0	
	HCV	Elecsys anti-HCV II (Roche)	Coagulopathy	83.3	96.3	95.2	86.7	
			Chronic kidney disease	93.5	99.2	95.6	98.7	
			HIV +ve					
(Saludes et al., 2019)	HCV	In-house RT-qPCR	HIV +ve	85.4 (72.8-92.8)	NR	NR	NR	~12 IU/mL
				87.2 (74.8-94)	NR	NR	NR	≥12 IU/mL
				97.6 (87.7-99.6)	NR	NR	NR	≥1,000 IU/mL
				97.6 (87.7-99.6)	NR	NR	NR	≥3,000 IU/mL
				100.0 (91.0-100.0)	NR	NR	NR	≥50,000 IU/mL
			HIV -ve	89.2 (83.2-93.2)	NR	NR	NR	~12 IU/mL
				91.0 (85.2-94.7)	NR	NR	NR	≥12 IU/mL
				95.6 (90.7-98.0)	NR	NR	NR	≥1,000 IU/mL
				97.0 (92.6-98.8)	NR	NR	NR	≥3,000 IU/mL
				100.0 (96.9-100.0)	NR	NR	NR	≥50,000 IU/mL

NPV=negative predictive value; NA = not applicable; NR=not reported; PPV=positive predictive value;  
STBBI=sexually transmitted and blood-borne infection;

**Table 5**

*Studies assessing test performance on DBS specimens collected from participants undergoing ART and ART-naïve participants*

Study	STBBI	Index Test	Participants	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	Notes
(P. Alvarez et al., 2015)	HIV	COBAS AmpliPrep/COBAS TaqMan HIV-1 Quantitative Test v2.0 (Roche)	ART-naïve	94.7 (74.0-99.9)	90.5 (77.4-97.3)	NR	NR	
			Undergoing ART	96.2 (86.8-99.5)	90.5 (80.4-96.4)	NR	NR	
			All	95.8 (88.1-99.1)	89.5 (82.0-94.7)	NR	NR	
		Versant HIV-1 RNA 1.0 (Siemens)	ART-naïve	84.2 (60.4-96.6)	100.0 (91.0-100.0)	NR	NR	
			Undergoing ART	64.7 (50.4-77.6)	100.0 (93.4-100.0)	NR	NR	
			All	70.0 (57.9-80.4)	100.0 (96.1-100.0)	NR	NR	
(Balinda et al., 2016)	HIV	In-house RT-qPCR	ART-naïve	79.4	54.5	89.0	36.4	
			Undergoing ART (>6 months)	75.7	95.5	65.1	97.3	
			Undergoing ART (12-36 months)	88.9	98.1	72.7	99.3	
(Ondoa et al., 2014)		COBAS AmpliPrep/COBAS TaqMan HIV-1 Quantitative Test v2.0 (Roche)	ART-naïve	61.9	99.0	NR	NR	≥5,000 copies/mL
			Undergoing ART	9.0	100.0	NR	NR	≥5,000 copies/mL
(Taieb et al., 2018)		m2000SP, m2000RT (Abbott)	Undergoing ART (<6 months)	87.5 (47.3-99.7)	87.1 (70.1-96.4)	NR	NR	
			Undergoing ART (≥6 months)	85.2 (66.3-95.6)	99.0 (94.3-100.0)	NR	NR	
			All	90.1 (80.7-95.9)	96.2 (91.4-98.8)	NR	NR	

Aitken, S. C., Kliphuis, A., Bronze, M., Wallis, C. L., Kityo, C., Balinda, S., . . . Schuurman, R. (2013). Development and Evaluation of an Affordable Real-Time Qualitative Assay for Determining HIV-1 Virological Failure in Plasma and Dried Blood Spots. *Journal of Clinical Microbiology*, 51(6), 1899-1905. doi:10.1128/JCM.03305-12

Alexander, T. S. (2016). Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. *Clinical and Vaccine Immunology*, 23(4), 249-253. doi:10.1128/CVI.00053-16

Alvarez, P., Martin, L., Prieto, L., Obiang, J., Vargas, A., Avedillo, P., . . . Holguin, A. (2015). HIV-1 variability and viral load technique could lead to false positive HIV-1 detection and to erroneous viral quantification in infected specimens. *J Infect*, 71(3), 368-376. doi:10.1016/j.jinf.2015.05.011

Alvarez, P., Martin, L., Prieto, L., Obiang, J., Vargas, A., Avedillo, P., . . . Holguin, A. (2015). HIV-1 Variability and Viral Load Technique Could Lead to False Positive HIV-1 Detection and to Erroneous Viral Quantification in Infected Specimens. *Journal of Infection*, 71, 368-376. doi:10.1016/j.jinf.2015.05.011

Amini, F., Auma, E., Hsia, Y., Bilton, S., Hall, T., Ramkhalawon, L., . . . Le Doare, K. (2021). Reliability of Dried Blood Spot (DBS) Cards in Antibody Measurement: A Systematic Review. *PLoS ONE*, 16(3), e0248218. doi:10.1371/journal.pone.0248218

Andreotti, M., Pirillo, M., Guidotti, G., Ceffa, S., Paturzo, G., Germano, P., . . . Giuliano, M. (2010). Correlation Between HIV-1 Viral Load Quantification in Plasma, Dried Blood Spots, and Dried Plasma Spots Using the Roche COBAS Taqman Assay. *Journal of Clinical Virology*, 47(1), 4-7. doi:10.1016/j.jcv.2009.11.006

Balinda, S. N., Ondo, P., Obuku, E. A., Kliphuis, A., Egau, I., Bronze, M., . . . consortium, A.-A. (2016). Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda. *PLoS ONE*, 11(1), e0145110. doi:10.1371/journal.pone.0145110

Bargain, P., Heslan, C., Thibault, V., & Pronier, C. (2020). Combined Use of Dried Blood Spot and Rapid Molecular Systems: A Robust Solution to Monitor Hepatitis B Virus Infection with Potential for Resource-Limited Countries. *Journal of Virological Methods*, 283, 113908. doi:10.1016/j.jviromet.2020.113908

Bennett, S., Gunson, R. N., McAllister, G. E., Hutchinson, S. J., Goldberg, D. J., Cameron, S. O., & Carman, W. F. (2012). Detection of Hepatitis C virus RNA in Dried Blood Spots. *Journal of Clinical Virology*, 54(2), 106-109. doi:10.1016/j.jcv.2012.02.004

- Bezerra, C. S., Portilho, M. M., Barbosa, J. R., de Azevedo, C. P., Mendonca, A., da Cruz, J. N. M., . . . Villar, L. M. (2022). Dried Blood Spot Sampling for Hepatitis B Virus Quantification, Sequencing and Mutation Detection. *Scientific Reports*, 12(1), 1651. doi:10.1038/s41598-022-05264-1
- Bezerra, C. S., Portilho, M. M., Frota, C. C., & Villar, L. M. (2021). Comparison of Four Extraction Methods for the Detection of Hepatitis B Virus DNA in Dried Blood Spot Samples. *Microbiologyopen*, 10(2), e1161. doi:10.1002/mbo3.1161
- Biondi, M. J., van Tilborg, M., Smookler, D., Heymann, G., Aquino, A., Perusini, S., . . . Feld, J. J. (2019). Hepatitis C Core-Antigen Testing from Dried Blood Spots. *Viruses*, 11(9). doi:10.3390/v11090830
- Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., . . . Group, S. (2015). STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. *BMJ*, 351, h5527. doi:10.1136/bmj.h5527
- Brandão, C. P., Marques, B. L., Marques, V. A., Villela-Nogueira, C. A., Do, O. K., de Paula, M. T., . . . Villar, L. M. (2013). Simultaneous Detection of Hepatitis C Virus Antigen and Antibodies in Dried Blood Spots. *Journal of Clinical Virology*, 57(2), 98-102. doi:10.1016/j.jcv.2013.02.014
- Buckton, A. J. (2008). New Methods for the Surveillance of HIV Drug Resistance in the Resource Poor World. *Current Opinion in Infectious Diseases*, 21(6), 653-658. doi:10.1097/QCO.0b013e3283186d1a
- Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., . . . Wittwer, C. T. (2009). The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. *Clinical Chemistry*, 55(4), 611-622. doi:10.1373/clinchem.2008.112797
- Catlett, B., Carrera, A., Starr, M., Applegate, T. L., Lowe, P., Grebely, J., & Philip Cunningham, H. (2019). Performance Evaluation of the Hologic Aptima HCV Quant Dx Assay for Detection of HCV RNA from Dried Blood Spots. *Journal of Clinical Virology*, 112, 40-44. doi:10.1016/j.jcv.2019.01.010
- Chevaliez, S., & Pawlotsky, J. M. (2018). New Virological Tools for Screening, Diagnosis and Monitoring of Hepatitis B and C in Resource-Limited Settings. *Journal of Hepatology*, 69(4), 916-926. doi:10.1016/j.jhep.2018.05.017
- Cholette, F., Fabia, R., Harris, A., Ellis, H., Cachero, K., Schroeder, L., . . . Kim, J. (2022). Comparative Performance Data for Multiplex SARS-CoV-2 Serological Assays from a Large Panel of Dried Blood Spot Specimens. *Heliyon*, 8(9), e10270. doi:10.1016/j.heliyon.2022.e10270

Choudhary, I., Chimanpure, V., Patil, A., Mukhopadhyaya, R., Paranjape, R., & Bhattacharya, J. (2013). Single Step Detection of HIV-1 Proviral DNA and Housekeeping Beta-Actin Gene from Dried Blood Spots by a Monoplex Polymerase Chain Reaction. *Journal of Virological Methods*, 187(1), 203-206. doi:10.1016/j.jviromet.2012.08.012

De Crignis, E., Re, M. C., Cimatti, L., Zecchi, L., & Gibellini, D. (2010). HIV-1 and HCV Detection in Dried Blood Spots by SYBR Green Multiplex Real-Time RT-PCR. *Journal of Virological Methods*, 165(1), 51-56. doi:10.1016/j.jviromet.2009.12.017

Dore, G. J., & Bajis, S. (2021). Hepatitis C Virus Elimination: Laying the Foundation for Achieving 2030 Targets. *Nature Reviews Gastroenterology & Hepatology*, 18(2), 91-92. doi:10.1038/s41575-020-00392-3

Erba, F., Brambilla, D., Ceffa, S., Ciccacci, F., Luhanga, R., Sidumo, Z., . . . Giuliano, M. (2015). Measurement of Viral Load by the Automated Abbott Real-Time HIV-1 Assay Using Dried Blood Spots Collected and Processed in Malawi and Mozambique. *South African Medical Journal*, 105(12), 1036-1038. doi:10.7196/SAMJ.2015.v105i12.9673

Fajardo, E., Metcalf, C. A., Chaillet, P., Aleixo, L., Pannus, P., Panunzi, I., . . . Mwenda, R. (2014). Prospective Evaluation of Diagnostic Accuracy of Dried Blood Spots from Finger Prick Samples for Determination of HIV-1 Load with the NucliSENS Easy-Q HIV-1 Version 2.0 Assay in Malawi. *Journal of Clinical Microbiology*, 52(5), 1343-1351. doi:10.1128/jcm.03519-13

Fiscus, S. A., Brambilla, D., Grosso, L., Schock, J., & Cronin, M. (1998). Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma by Using Blood Dried on Filter Paper. *Journal of Clinical Microbiology*, 36(1), 258-260. doi:10.1128/jcm.36.1.258-260.1998

Flores, G. L., Barbosa, J. R., Cruz, H. M., Miguel, J. C., Potsch, D. V., Pilotto, J. H., . . . Villar, L. M. (2021). Dried Blood Spot Sampling as an Alternative for the Improvement of Hepatitis B and C Diagnosis in Key Populations. *World Journal of Hepatology*, 13(4), 504-514. doi:10.4254/wjh.v13.i4.504

Flores, G. L., Cruz, H. M., Marques, V. A., Villela-Nogueira, C. A., Potsch, D. V., May, S. B., . . . Villar, L. M. (2017). Performance of ANTI-HCV Testing in Dried Blood Spots and Saliva According to HIV Status. *Journal of Medical Virology*, 89(8), 1435-1441. doi:10.1002/jmv.24777

Flores, G. L., Cruz, H. M., Miguel, J. C., Potsch, D. V., Pilotto, J. H., Lewis-Ximenez, L. L., . . . Villar, L. M. (2018). Assessing Hepatitis B Immunity Using Dried Blood Spot Samples from HIV+ Individuals. *Journal of Medical Virology*, 90(12), 1863-1867. doi:10.1002/jmv.25275

Flores, G. L., Cruz, H. M., Potsch, D. V., May, S. B., Brandao-Mello, C. E., Pires, M. M. A., . . . Villar, L. M. (2017). Evaluation of HBsAg and Anti-HBc Assays in Saliva and Dried Blood Spot Samples According HIV Status. *Journal of Virological Methods*, 247, 32-37. doi:10.1016/j.jviromet.2017.05.004

García-Cisneros, S., Sanchez-Aleman, M. A., Conde-Glez, C. J., Lara-Zaragoza, S. J., Herrera-Ortiz, A., Plett-Torres, T., & Olamendi-Portugal, M. (2019). Performance of ELISA and Western Blot to Detect Antibodies Against HSV-2 Using Dried Blood Spots. *Journal of Infection and Public Health*, 12(2), 224-228. doi:10.1016/j.jiph.2018.10.007

Gobran, S. T., Ancuta, P., & Shoukry, N. H. (2021). A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection. *Frontiers in Immunology*, 12, 726419. doi:10.3389/fimmu.2021.726419

Gruner, N., Stambouli, O., & Ross, R. S. (2015). Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques. *Journal of Visualized Experiments*, 97, e52619. doi:10.3791/52619

Guichet, E., Serrano, L., Laurent, C., Eymard-Duvernay, S., Kuaban, C., Vidal, L., . . . Peeters, M. (2018). Comparison of Different Nucleic Acid Preparation Methods to Improve Specific HIV-1 RNA Isolation for Viral Load Testing on Dried Blood Spots. *Journal of Virological Methods*, 251, 75-79. doi:10.1016/j.jviromet.2017.10.014

Halfon, P., Raimondo, A., Ouzan, D., Bourliere, M., Khiri, H., Cohen-Bacrie, S., . . . Dukan, P. (2012). Dried Blood Spot for Hepatitis B Virus Serology and Molecular Testing. *Journal of Hepatology*, 56, S61-69. doi:10.1016/S0168-8278(12)60155-X

Hobbs, M. M., Mwanyumba, S. W., Luseno, W. K., Hartman, S., Halpern, C. T., Hallfors, D. D., & Cho, H. (2017). Evaluation of Herpes Simplex Virus Type 2 Serological Tests for Use With Dried Blood Spots in Kenya. *Sexually Transmitted Diseases*, 44(2), 101-103. doi:10.1097/olq.0000000000000557

Huang, S., Erickson, B., Mak, W. B., Salituro, J., & Abravaya, K. (2011). A Novel RealTime HIV-1 Qualitative Assay for the Detection of HIV-1 Nucleic Acids in Dried Blood Spots and Plasma. *Journal of Virological Methods*, 178(1-2), 216-224. doi:10.1016/j.jviromet.2011.09.015

Jackson, K., Holgate, T., Tekoa, R., Nicholson, S., Littlejohn, M., & Locarnini, S. (2022). Evaluation of Dried Blood Spots for Hepatitis B and D Serology and Nucleic Acid Testing. *Journal of Medical Virology*, 94(2), 642-648. doi:10.1002/jmv.25485

Jardi, R., Rodriguez-Frias, F., Buti, M., Schaper, M., Valdes, A., Martinez, M., . . . Guardia, J. (2004). Usefulness of Dried Blood Samples for Quantification and Molecular Characterization of HBV-DNA. *Hepatology*, 40(1), 133-139. doi:10.1002/hep.20275

Judd, A., Parry, J., Hickman, M., McDonald, T., Jordan, L., Lewis, K., . . . Nelson, M. (2003). Evaluation of a Modified Commercial Assay in Detecting Antibody to Hepatitis C Virus in Oral Fluids and Dried Blood Spots. *Journal of Virological Methods*, 71(1), 49-55. doi:10.1002/jmv.10463

Kane, C. T., Ndiaye, H. D., Diallo, S., Ndiaye, I., Wade, A. S., Diaw, P. A., . . . Mboup, S. (2008). Quantitation of HIV-1 RNA in Dried Blood Spots by the Real-Time NucliSENS EasyQ HIV-1 Assay in Senegal. *Journal of Virological Methods*, 148(1-2), 291-295. doi:10.1016/j.jviromet.2007.11.011

Kerschberger, B., Ntshalintshali, N., Mpala, Q., Diaz Uribe, P. A., Maphalala, G., Kalombola, S., . . . Fajardo, E. (2019). Field Suitability and Diagnostic Accuracy of the Biocentric Open Real-Time PCR Platform for Dried Blood Spot-Based HIV Viral Load Quantification in Eswatini. *Journal of Acquired Immune Deficiency Syndromes*, 82(1), 96-104. doi:10.1097/qai.0000000000002101

Landy, R., Atkinson, D., Ogilvie, K., St Denys, R., Lund, C., Worthington, C., . . . team, S. (2022). Assessing the Acceptability of Dried Blood Spot Testing for HIV and STBBI Among Metis People in a Community Driven Pilot Project in Alberta, Canada. *BMC Health Services Research*, 22(1), 1496. doi:10.1186/s12913-022-08763-z

Lim, M. D. (2018). Dried Blood Spots for Global Health Diagnostics and Surveillance: Opportunities and Challenges. *American Journal of Tropical Medicine and Hygiene*, 99(2), 256-265. doi:10.4269/ajtmh.17-0889

Lira, R., Maldonado-Rodriguez, A., Rojas-Montes, O., Ruiz-Tachiquin, M., Torres-Ibarra, R., Cano-Dominguez, C., . . . Alvarez-Munoz, M. T. (2009). Use of Dried Blood Samples for Monitoring Hepatitis B Virus Infection. *Virology Journal*, 6, 153. doi:10.1186/1743-422x-6-153

Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., . . . Mutevedzi, P. C. (2022). Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. *New England Journal of Medicine*, 386(14), 1314-1326. doi:10.1056/NEJMoa2119658



- 628 Mahajan, S., Choudhary, M. C., Kumar, G., & Gupta, E. (2018). Evaluation of Dried Blood Spot as an Alternative  
629 Sample Collection Method for Hepatitis C Virus RNA Quantitation and Genotyping Using a Commercial  
630 System. *Virusdisease*, 29(2), 141-146. doi:10.1007/s13337-018-0441-9
- 631 Makadzange, A. T., Boyd, F. K., Chimukangara, B., Masimirembwa, C., Katzenstein, D., & Ndhlovu, C. E. (2017). A  
632 Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load  
633 Monitoring Using Dried Blood Spots. *Journal of Clinical Microbiology*, 55(7), 2172-2179. doi:10.1128/jcm.00176-  
634 17
- 635 Malsagova, K., Kopylov, A., Stepanov, A., Butkova, T., Izotov, A., & Kaysheva, A. (2020). Dried Blood Spot in  
636 Laboratory: Directions and Prospects. *Diagnostics*, 10(4). doi:10.3390/diagnostics10040248
- 637 Marconi, A., Balestrieri, M., Comastri, G., Pulvirenti, F. R., Gennari, W., Tagliazucchi, S., . . . Zazzi, M. (2009).  
638 Evaluation of the Abbott Real-Time HIV-1 Quantitative Assay with Dried Blood Spot Specimens. *Clinical*  
639 *Microbiology and Infection*, 15(1), 93-97. doi:10.1111/j.1469-0691.2008.02116.x
- 640 Marques, B. L., Brandao, C. U., Silva, E. F., Marques, V. A., Villela-Nogueira, C. A., Do, O. K., . . . Villar, L. M. (2012).  
641 Dried Blood Spot Samples: Optimization of Commercial EIAs for Hepatitis C Antibody Detection and  
642 Stability Under Different Storage Conditions. *Journal of Medical Virology*, 84(10), 1600-1607.  
643 doi:10.1002/jmv.23379
- 644 Marques, B. L. C., do Espirito-Santo, M. P., Marques, V. A., Miguel, J. C., da Silva, E. F., Villela-Nogueira, C. A., . . .  
645 Villar, L. M. (2016). Evaluation of Dried Blood Spot Samples for Hepatitis C Virus Detection and  
646 Quantification. *Journal of Clinical Virology*, 82, 139-144. doi:10.1016/j.jcv.2016.07.009
- 647 Mavedzenge, S. N., Davey, C., Chirenje, T., Mushati, P., Mtetwa, S., Dirawo, J., . . . Cowan, F. M. (2015). Finger Prick  
648 Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe. *PLoS ONE*, 10(5),  
649 e0126878. doi:10.1371/journal.pone.0126878
- 650 Mays, N., Pope, C., & Popay, J. (2005). Systematically Reviewing Qualitative and Quantitative Evidence to Inform  
651 Management and Policy-Making in the Health Field. *Journal of Health Services Research & Policy*,  
652 10(Supplement 1), 6-20.
- 653 McArdle, A. J., Turkova, A., & Cunningham, A. J. (2018). When do Co-Infections Matter? *Current Opinion in Infectious*  
654 *Diseases*, 31(3), 209-215. doi:10.1097/QCO.0000000000000447

McCarron, B., Fox, R., Wilson, K., Cameron, S., McMenamin, J., McGregor, G., . . . Goldberg, D. (1999). Hepatitis C Antibody Detection in Dried Blood Spots. *Journal of Viral Hepatitis*, 6(6), 453-456. doi:10.1046/j.1365-2893.1999.00197.x

McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016). PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical Epidemiology*, 75, 40-46. doi:10.1016/j.jclinepi.2016.01.021

Miesse, P. K., Collier, B. B., & Grant, R. P. (2022). Monitoring of SARS-CoV-2 Antibodies Using Dried Blood Spot for At-Home Collection. *Scientific Reports*, 12(1), 5812. doi:10.1038/s41598-022-09699-4

Mohamed, S., Raimondo, A., Penaranda, G., Camus, C., Ouzan, D., Ravet, S., . . . Halfon, P. (2013). Dried Blood Spot Sampling for Hepatitis B Virus Serology and Molecular Testing. *PLoS ONE*, 8(4), e61077. doi:10.1371/journal.pone.0061077

Mwau, M., Danda, J., Mbugua, J., Handa, A., Fortunko, J., Worlock, A., & Nair, S. V. (2021). Prospective Evaluation of Accuracy of HIV Viral Load Monitoring Using the Aptima HIV Quant Dx Assay with Fingertick and Venous Dried Blood Spots Prepared Under Field Conditions in Kenya. *PLoS ONE*, 16(4), e0249376. doi:10.1371/journal.pone.0249376

Neogi, U., Gupta, S., Rodridges, R., Sahoo, P. N., Rao, S. D., Rewari, B. B., . . . Shet, A. (2012). Dried Blood Spot HIV-1 RNA Quantification: A Useful Tool for Viral Load Monitoring Among HIV-Infected Individuals in India. *Indian Journal of Medical Research*, 136(6), 956-962. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23391790>

Nguyen, T. T., Lemee, V., Bollore, K., Vu, H. V., Lacombe, K., Thi, X. L. T., . . . Tuaillon, E. (2018). Confirmation of HCV Viremia Using HCV RNA and Core Antigen Testing on Dried Blood Spot in HIV Infected Peoples Who Inject Drugs in Vietnam. *BMC Infectious Diseases*, 18(1), 622. doi:10.1186/s12879-018-3529-3

Noda, S., Eizuru, Y., Minamishima, Y., Ikenoue, T., & Mori, N. (1993). Detection of Human T-Cell Lymphotropic Virus Type 1 Infection by the Polymerase Chain Reaction Using Dried Blood Specimens on Filter Papers. *Journal of Virological Methods*, 43(1), 111-122. doi:10.1016/0166-0934(93)90094-8

Nugent, C. T., Dockter, J., Bernardin, F., Hecht, R., Smith, D., Delwart, E., . . . Giachetti, C. (2009). Detection of HIV-1 in Alternative Specimen Types Using the APTIMA HIV-1 RNA Qualitative Assay. *Journal of Virological Methods*, 159(1), 10-14. doi:10.1016/j.jviromet.2009.02.015

Ondoa, P., Shamu, T., Bronze, M., Wellington, M., Boender, T. S., Manting, C., . . . Rinke de Wit, T. (2014). Performance and Logistical Challenges of Alternative HIV-1 Virological Monitoring Options in a Clinical Setting of Harare, Zimbabwe. *BioMed Research International*, 2014, 102598. doi:10.1155/2014/102598

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., . . . Moher, D. (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. *BMJ*, 372, n71. doi:10.1136/bmj.n71

Pannus, P., Fajardo, E., Metcalf, C., Coulborn, R. M., Duran, L. T., Bygrave, H., . . . Preiser, W. (2013). Pooled HIV-1 Viral Load Testing Using Dried Blood Spots to Reduce the Cost of Monitoring Antiretroviral Treatment in a Resource-Limited Setting. *Journal of Acquired Immune Deficiency Syndromes*, 64(2), 134-137. doi:10.1097/QAI.0b013e3182a61e63

Parr, J. B., Lodge, E. K., Holzmayer, V., Pepin, J., Frost, E. H., Fried, M. W., . . . Cloherty, G. (2018). An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. *Clinical Infectious Diseases*, 66(2), 254-260. doi:10.1093/cid/cix771

Pirillo, M. F., Recordon-Pinson, P., Andreotti, M., Mancini, M. G., Amici, R., & Giuliano, M. (2011). Quantification of HIV-RNA from Dried Blood Spots Using the Siemens VERSANT HIV-1 RNA (kPCR) assay. *Journal of Antimicrobial Chemotherapy*, 66(12), 2823-2826. doi:10.1093/jac/dkr383

Pollack, T. M., Duong, H. T., Truong, P. T., Pham, T. T., Do, C. D., & Colby, D. (2018). Sensitivity and Specificity of Two Dried Blood Spot Methods for HIV-1 Viral Load Monitoring Among Patients in Hanoi, Vietnam. *PLoS ONE*, 13(1), e0191411. doi:10.1371/journal.pone.0191411

Prinsenbergh, T., Rebers, S., Boyd, A., Zuure, F., Prins, M., van der Valk, M., & Schinkel, J. (2020). Dried Blood Spot Self-Sampling at Home is a Feasible Technique for Hepatitis C RNA Detection. *PLoS ONE*, 15(4), e0231385. doi:10.1371/journal.pone.0231385

Roberts, C. P., & Klausner, J. D. (2016). Global Challenges in Human Immunodeficiency Virus and Syphilis Co-Infection Among Men Who Have Sex With Men. *Expert Review of Anti-Infective Therapy*, 14(11), 1037-1046. doi:10.1080/14787210.2016.1236683

Roger, S., Lefeuvre, C., Grison, M., Ducancelle, A., Lunel-Fabiani, F., Pivert, A., & Le Guillou-Guillemette, H. (2020). Evaluation of the Aptima HBV Quant Dx Assay for Semi-Quantitative HBV Viral Load from Dried Blood Spots. *Journal of Clinical Virology*, 129, 104524. doi:10.1016/j.jcv.2020.104524

Rutstein, S. E., Kamwendo, D., Lugali, L., Thengolose, I., Tegha, G., Fiscus, S. A., . . . Mataya, R. (2014). Measures of Viral Load Using Abbott RealTime HIV-1 Assay on Venous and Fingertick Dried Blood Spots from Provider-Collected Specimens in Malawian District Hospitals. *Journal of Clinical Virology*, 60(4), 392-398. doi:10.1016/j.jcv.2014.05.005

Saludes, V., Antuori, A., Folch, C., Gonzalez, N., Ibanez, N., Majo, X., . . . HepCdetect, I. I. S. G. (2019). Utility of a One-Step Screening and Diagnosis Strategy for Viremic HCV Infection Among People Who Inject Drugs in Catalonia. *International Journal of Drug Policy*, 74, 236-245. doi:10.1016/j.drugpo.2019.10.012

Saludes, V., Antuori, A., Lazarus, J. V., Folch, C., Gonzalez-Gomez, S., Gonzalez, N., . . . Martro, E. (2020). Evaluation of the Xpert HCV VL Fingertick Point-of-Care Assay and Dried Blood Spot HCV-RNA Testing as Simplified Diagnostic Strategies Among People Who Inject Drugs in Catalonia, Spain. *International Journal of Drug Policy*, 80, 102734. doi:10.1016/j.drugpo.2020.102734

Saludes, V., Folch, C., Morales-Carmona, A., Ferrer, L., Fernandez-Lopez, L., Munoz, R., . . . Martro, E. (2018). Community-Based Screening of Hepatitis C with a One-Step RNA Detection Algorithm from Dried-Blood Spots: Analysis of Key Populations in Barcelona, Spain. *Journal of Viral Hepatitis*, 25(3), 236-244. doi:10.1111/jvh.12809

Santos, C., Reis, A., Dos Santos, C. V., Damas, C., Silva, M. H., Viana, M. V., . . . Diaz, R. S. (2012). The Use of Real-Time PCR to Detect Hepatitis C Virus RNA in Dried Blood Spots from Brazilian Patients Infected Chronically. *Journal of Virological Methods*, 179(1), 17-20. doi:10.1016/j.jviromet.2011.06.012

Sawadogo, S., Shiningavamwe, A., Chang, J., Maher, A. D., Zhang, G., Yang, C., . . . Lowrance, D. W. (2014). Limited Utility of Dried-Blood- and Plasma Spot-Based Screening for Antiretroviral Treatment Failure with Cobas

Ampliprep/TaqMan HIV-1 version 2.0. *Journal of Clinical Microbiology*, 52(11), 3878-3883.  
doi:10.1128/jcm.02063-14

Schmitz, M. E., Agolory, S., Junghae, M., Broyles, L. N., Kimeu, M., Ombayo, J., . . . for, V. L. D. B. S. S. G. (2017). Field Evaluation of Dried Blood Spots for HIV-1 Viral Load Monitoring in Adults and Children Receiving Antiretroviral Treatment in Kenya: Implications for Scale-up in Resource-Limited Settings. *Journal of Acquired Immune Deficiency Syndromes*, 74(4), 399-406. doi:10.1097/qai.0000000000001275

Shayan, S. J., Nazari, R., & Kiwanuka, F. (2021). Prevalence of HIV and HCV Among Injecting Drug Users in Three Selected WHO-EMRO Countries: A Meta-Analysis. *Harm Reduction Journal*, 18(1), 59. doi:10.1186/s12954-021-00505-4

Shepherd, S. J., Baxter, R. E., & Gunson, R. N. (2019). Evaluation of the Abbott m2000 System for Dried Blood Spot Detection of Hepatitis C virus RNA. *Journal of Clinical Virology*, 110, 7-10. doi:10.1016/j.jcv.2018.10.008

Sherman, G. G., Stevens, G., Jones, S. A., Horsfield, P., & Stevens, W. S. (2005). Dried Blood Spots Improve Access to HIV Diagnosis and Care for Infants in Low-Resource Settings. *Journal of Acquired Immune Deficiency Syndromes*, 38(5), 615-617.

Shimakawa, Y., Vernoux, L., Gabassi, A., Mercier-Delarue, S., Vincent, J. P., Simon, F., & Maylin, S. (2021). Analytical Validation of Hepatitis B Core-Related Antigen (HBcrAg) Using Dried Blood Spots (DBS). *Journal of Viral Hepatitis*, 28(5), 837-843. doi:10.1111/jvh.13489

Solmone, M., Girardi, E., Costa, F., Pucillo, L., Ippolito, G., & Capobianchi, M. R. (2002). Simple and Reliable Method for Detection and Genotyping of Hepatitis C Virus RNA in Dried Blood Spots Stored at Room Temperature. *Journal of Clinical Microbiology*, 40(9), 3512-3514. doi:10.1128/jcm.40.9.3512-3514.2002

Stene-Johansen, K., Yaqoob, N., Overbo, J., Abera, H., Desalegn, H., Berhe, N., & Johannessen, A. (2016). Dry Blood Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. *PLoS ONE*, 11(11), e0166201. doi:10.1371/journal.pone.0166201

Taieb, F., Tram, T. H., Ho, H. T., Pham, V. A., Nguyen, L., Pham, B. H., . . . Madec, Y. (2016). Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). *Open Forum Infectious Diseases*, 3(3), ofw142. doi:10.1093/ofid/ofw142

Taieb, F., Tran Hong, T., Ho, H. T., Nguyen Thanh, B., Pham Phuong, T., Viet Ta, D., . . . Madec, Y. (2018). First Field Evaluation of the Pptimized CE Marked Abbott Protocol for HIV RNA Testing on Dried Blood Spot in a Routine Clinical Setting in Vietnam. *PLoS ONE*, 13(2), e0191920. doi:10.1371/journal.pone.0191920

Takano, M., Iwahashi, K., Satoh, I., Araki, J., Kinami, T., Ikushima, Y., . . . Group, H. I. V. C. S. (2018). Assessment of HIV Prevalence Among MSM in Tokyo Using Self-Collected Dried Blood Spots Delivered Through the Postal Service. *BMC Infectious Diseases*, 18(1), 627. doi:10.1186/s12879-018-3491-0

Tang, N., Pahalawatta, V., Frank, A., Bagley, Z., Viana, R., Lampinen, J., . . . Wallis, C. L. (2017). HIV-1 Viral Load Measurement in Venous Blood and Fingerprick Blood Using Abbott RealTime HIV-1 DBS assay. *Journal of Clinical Virology*, 92, 56-61. doi:10.1016/j.jcv.2017.05.002

Templer, S. P., Seiverth, B., Baum, P., Stevens, W., Seguin-Devaux, C., & Carmona, S. (2016). Improved Sensitivity of a Dual-Target HIV-1 Qualitative Test for Plasma and Dried Blood Spots. *Journal of Clinical Microbiology*, 54(7), 1877-1882. doi:10.1128/jcm.00128-16

Tola, M., Habib, R. O., Sylvia, A., Crowell, T. A., Rebecca, N. G., Charurat, M. E., . . . Ndembu, N. (2021). Field Evaluation of HIV-1 Viral Load Monitoring in Adults and Children Receiving Antiretroviral Treatment in Nigeria by Dried Blood Spot Testing with RealTime HIV-1 on m2000. *Journal of Clinical Virology*, 135, 104694. doi:10.1016/j.jcv.2020.104694

Tran, T. H., Nguyen, B. T., Nguyen, T. A., Pham, T. T. P., Nguyen, T. T. T., Mai, H. T. B., . . . Madec, Y. (2020). Dried Blood Spots Perform Well to Identify Patients with Active HCV Infection in Vietnam. *Journal of Viral Hepatitis*, 27(5), 514-519. doi:10.1111/jvh.13263

Tuaillon, E., Mondain, A. M., Meroueh, F., Ottomani, L., Picot, M. C., Nagot, N., . . . Ducos, J. (2010). Dried blood spot for hepatitis C virus serology and molecular testing. *Hepatology*, 51(3), 752-758. doi:10.1002/hep.23407

UNAIDS. (2014). *Fast-Track: Ending the AIDS Epidemic by 2030*. Retrieved from Geneva, Switzerland:

van Deursen, P., Oosterlaken, T., Andre, P., Verhoeven, A., Bertens, L., Traub, M. A., . . . de Jong, J. (2010). Measuring Human Immunodeficiency Virus Type 1 RNA Loads in Dried Blood Spot Specimens Using NucliSENS EasyQ HIV-1 v2.0. *Journal of Clinical Virology*, 47(2), 120-125. doi:10.1016/j.jcv.2009.11.021

Vazquez-Moron, S., Ryan, P., Ardizzone-Jimenez, B., Martin, D., Troya, J., Cuevas, G., . . . Resino, S. (2018). Evaluation of Dried Blood Spot Samples for Screening of Hepatitis C and Human Immunodeficiency Virus in a Real-World Setting. *Scientific Reports*, 8(1), 1858. doi:10.1038/s41598-018-20312-5

Vetter, B. N., Reipold, E. I., Ongarello, S., Fajardo, E., Tyshkovskiy, A., Ben, I., & Vasylyev, M. (2021). Prospective Evaluation of Hepatitis C Virus Antibody Detection in Whole Blood Collected on Dried Blood Spots with the INNOTEST HCV Ab IV Enzyme Immunoassay. *Journal of Clinical Virology*, 137, 104783. doi:10.1016/j.jcv.2021.104783

Vidya, M., Saravanan, S., Rifkin, S., Solomon, S. S., Waldrop, G., Mayer, K. H., . . . Balakrishnan, P. (2012). Dried Blood Spots Versus Plasma for the Quantitation of HIV-1 RNA Using a Real-Time PCR, m2000rt Assay. *Journal of Virological Methods*, 181(2), 177-181. doi:10.1016/j.jviromet.2012.02.006

Viljoen, J., Gampini, S., Danaviah, S., Valea, D., Pillay, S., Kania, D., . . . World Health Organization, A. K. B. S. G. (2010). Dried Blood Spot HIV-1 RNA Quantification Using Open Real-Time Systems in South Africa and Burkina Faso. *Journal of Acquired Immune Deficiency Syndromes*, 55(3), 290-298. doi:10.1097/QAI.0b013e3181edaaf5

Villar, L. M., de Oliveira, J. C., Cruz, H. M., Yoshida, C. F., Lampe, E., & Lewis-Ximenez, L. L. (2011). Assessment of Dried Blood Spot Samples as a Simple Method for Detection of Hepatitis B Virus Markers. *Journal of Medical Virology*, 83(9), 1522-1529. doi:10.1002/jmv.22138

Vinikoor, M. J., Zurcher, S., Musukuma, K., Kachuwaire, O., Rauch, A., Chi, B. H., . . . Wandeler, G. (2015). Hepatitis B Viral Load in Dried Blood Spots: A Validation Study in Zambia. *Journal of Clinical Virology*, 72, 20-24. doi:10.1016/j.jcv.2015.08.019

Vojnov, L., Carmona, S., Zeh, C., Markby, J., Boeras, D., Prescott, M. R., . . . Consortium, D. B. S. f. V. D. I. (2022). The Performance of Using Dried Blood Spot Specimens for HIV-1 Viral Load Testing: A Systematic Review and Meta-Analysis. *PLoS Medicine*, 19(8), e1004076. doi:10.1371/journal.pmed.1004076

Weber, J., Sahoo, M. K., Taylor, N., Shi, R. Z., & Pinsky, B. A. (2019). Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. *Journal of Clinical Microbiology*, 57(4). doi:10.1128/jcm.00030-19

Whiting, P. F., Weswood, M. E., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. N., & Kleijnen, J. (2006). Evaluation of QUADAS, A Tool for the Quality Assessment of Diagnostic Accuracy Studies. *BMC Medical Research Methodology*, 6(9). doi:10.1186/1471-2288-6-9

Wilson P., P. J. B., Holzmayer V., Carrell M., Tshetu A., Mwandagaliwa K., Muwonga J., Fwamba F., Kuhns M., Jhaveri R., Meshnick S.R., Cloherty G. (2018). Efficient Dried Blood Spot-Based Determination of Hepatitis B Seroprevalence from a National Survey in the Democratic Republic of the Congo. *Journal of Viral Hepatitis*, 25(S2), 92-93. doi:10.1111/jvh.100\_12923

Wong, M. P., Meas, M. A., Adams, C., Hernandez, S., Green, V., Montoya, M., . . . Harris, E. (2022). Development and Implementation of Dried Blood Spot - Based COVID-19 Serological Assays for Epidemiologic Studies. *Microbiology Spectrum*, 10(3), e0247121.

Young, J., Ablona, A., Klassen, B. J., Higgins, R., Kim, J., Lavoie, S., . . . Lachowsky, N. J. (2022). Implementing Community-Based Dried Blood Spot (DBS) Testing for HIV and Hepatitis C: A Qualitative Analysis of Key Facilitators and Ongoing Challenges. *BMC Public Health*, 22(1), 1085. doi:10.1186/s12889-022-13525-x

Zeh, C., Ndiege, K., Inzaule, S., Achieng, R., Williamson, J., Chih-Wei Chang, J., . . . Nkengasong, J. (2017). Evaluation of the Performance of Abbott m2000 and Roche COBAS Ampliprep/COBAS Taqman Assays for HIV-1 Viral Load Determination Using Dried Blood Spots and Dried Plasma Spots in Kenya. *PLoS ONE*, 12(6), e0179316. doi:10.1371/journal.pone.0179316

Zhang, J., Zhang, L., Song, M., & Wang, W. (2010). Detection of HBV-DNA in Dried Bloodstains on Filter Paper by Nested Polymerase Chain Reaction. *Laboratory Medicine*, 41(9), 535-539. doi:10.1309/lmgvuu8etvjnx91y